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Abstract 
 
Sphingosine-1-Phosphate and the RGS RhoGEFs Regulate Vascular Smooth 
Muscle Phenotype 
 
(Under the direction of Christopher P. Mack, Ph.D.) 
The regulation of smooth muscle cell (SMC) differentiation is critical during 
vascular development, and perturbations in this process contribute to a number of 
cardiovascular pathologies including atherosclerosis, hypertension, and restenosis. 
We have shown that activation of RhoA by sphingosine-1 phosphate (S1P) 
stimulates SMC-specific gene expression by promoting the nuclear localization of 
the myocardin-related transcription factors (MRTFs). 
 The aim of this dissertation is to dissect the precise mechanisms by which 
S1P regulates SMC phenotype. Using a combination of receptor-specific agonists 
and antagonists we identified S1P2 as the driving S1P receptor sub-type that 
regulates SMC-specific promoter activity and differentiation marker gene expression 
in primary SMC cultures. In addition, over expression of Gα12 or Gα13 increased 
SMC specific transcription, a result in excellent agreement with the known G-protein 
coupling properties of S1P2.  Given previous studies on the interaction of Gα12/13 
with the RGS subfamily of RhoGEFs (LARG, PRG, P115), we hypothesized that one 
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or more of these RhoA activators was important in S1P-mediated SMC 
differentiation.  While expression of each of the RGS RhoGEFs activated SMC 
specific transcription, LARG exhibited the most robust effect invoking a 10 to 15 fold 
increase SM22 and SM α-actin promoter activity.  LARG expression also resulted in 
increased stress fiber formation and MRTF-A nuclear localization. Importantly, 
siRNA-mediated depletion of LARG (by approximately 90%) inhibited activation of 
RhoA by S1P and also inhibited the effects of S1P on endogenous SMC 
differentiation marker gene expression and SMC specific promoter activity. Finally, 
knockdown of LARG promoted SMC migration as measured by scratch wound and 
transwell assays.  These findings indicate that stimulation of RhoA activity by S1P2-
dependent activation of LARG plays a critical role in the regulation SMC phenotype. 
Interestingly P115 RhoGEF appears to regulate SMC migration in opposition to 
LARG.  Despite the importance of RGS RhoGEF signaling little is known about their 
regulation.  This thesis will explore the mechanisms regulating RGS RhoGEFs 
mediated RhoA activity and how differential RhoA activation may help modulate 
SMC phenotype.  In conclusion these studies have improved our understanding the 
very complex means by which S1P mediated signaling regulates SMC phenotype 
and by extension normal and pathological vascular development. 
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Chapter 1 
Background and Significance 
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Proper formation and maintenance of the vasculature is an ongoing and 
critical process, so important that the vasculature is the earliest organ to develop 
and requires more reconstruction and maintenance than any other organ system to 
remain functional.  The mature human vasculature is composed of an extensive 
network of arteries, veins, and capillaries charged with conducting chemical 
exchange necessary for the maintenance and function of organs and tissues.  
Disruption of these processes, brought about by perturbations in vascular function, 
contribute to a substantial portion of human disease. 
Vascular Development and Disease 
The genesis and maintenance of vasculature can be defined in three broad 
categories consisting of, vasculogenesis, angiogenesis, and vascular remodeling.  
Vasculogenesis begins when hemangioblasts differentiate into angioblasts, which 
become endothelial cells (ECs), and coalesce into primitive cords and tubes.  Once 
initial vessels are formed the process of angiogenesis or extensive sprouting from 
preexisting vessels occurs.  ECs provide a smooth, non thrombogenic surface to 
assist in circulation and are critical in the regulation of vasculogenesis, hemostasis, 
inflammation, and blood pressure. VEGF, Shh, and Notch signaling all play a role in 
EC-mediated vascular development (see [1] for review).  While the role of EC 
signaling in vascular regulation has been extensively studied the role of SMC 
signaling in this process is less well understood.  Smooth muscle cells are a critical 
and driving component of the normal and pathological development of mature 
arterial vasculature (see Figure 1.1). The molecular mechanisms that regulate their 
phenotypic modulation are of extreme importance in the maintenance of the  
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Figure 1.1. Structure of Arterial Vasculature in Healthy and Pathogenic States.   
A. Healthy arterial vasculature consists of 5 distinct layers including an intima 
composed of endothelial cells, an internal elastic lamina composed mainly of elastin, 
the tunica media composed of smooth muscle, an external elastic lamina composed 
mainly of elastin, and the tunica adventia or externa composed of fibrous tissues and 
ECM, mainly collagen. B. Neointimal hyperplasia is a pathogenic state that occurs 
after acute arterial injury to the intima.  The lesion results from accelerated migration 
and proliferation of SMC to form a very rigid lesion occluding the intimal space and 
impeding blood flow.  C.  A complex atherosclerotic lesion composed of monocytes, 
macrophages and mature foam cells, LDL molecules, SMC, and a necrotic core.  
SMCs can contribute to plaque instability through migration, proliferation, and even 
foam cell generation.  They also stabilize the fibrous cap, thereby serving a 
protective role in atherosclerosis. 
4 
 
vasculature and consequently the mortality associated with the disruption of these 
processes.  
As embryogenesis proceeds, the demands on the vasculature are greatly 
increased.  Soon the force and pressure associated with providing nutrients to the 
developing embryo require a more robust vascular network.  The dogma 
surrounding recruitment and investment of SMC in arterial vasculature suggests that 
increasing demand for vascular integrity promotes signals for recruitment of 
pericytes and smooth muscle cells.  Extensive  proliferation, differentiation, and 
remodeling of vascular SMC is necessary for proper vascular development.  The 
signals that regulate SMC in vascular development, maturation, and homeostasis is 
complex, varies thoughout the vasculature, and is at present poorly understood.  
The questions about what, where, when, and how these signals are interpreted can 
only be addressed with a more complete understanding of the multiple origins of 
SMC during embryogenesis and throughout development, and the extracellular cues 
that regulate these responses. 
Smooth Muscle Cells in Vascular Development and Disease  
The origins that give rise to smooth muscle are extensive and diverse.  Fate 
mapping studies have shown that smooth muscle arises from at least 7 distinct 
origins in vertebrate embryogenesis.  It is impossible to underscore the importance 
of this revelation in SMC development.  One layer of complexity arising from this 
mosaic tissue type is that smooth muscle arising from differing lineages have 
differing protein expression patterns and can respond to the same agonist in 
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completely different ways.  The coronary vasculature is thought to arise from the 
proepicardial mesothelium [2].  SMCs that comprise portions of the ascending aorta 
arise from the neural crest, SMCs that make up the descending aorta arise from 
splanchic mesoderm.  Additionally the secondary heart field, pericytes, mesothelium, 
somites, and  mesoangioblasts also contribute to discrete populations of SMC (see 
[3, 4] for review).  It is physiologically relevant that disease progression, under 
identical circumstances, occurs at different rates depending on the SMC origin [5, 6].  
The best example is the propensity for coronary vasculature, a SMC of proepicardial 
origin, to develop advanced arterial lesions much faster than arteries composed of 
SMC from other origins [7]. 
Regardless of the multitude of SMC origins, the tissue as a whole is 
remarkably similar in both function and phenotype.   Smooth muscle differs from 
cardiac and skeletal muscle in a number of ways.  Unlike skeletal and cardiac 
muscle, smooth muscle is not terminally differentiated.   Robust expression of 
polymerized actin and stress fibers is a hallmark of differentiated SMCs.  Structurally 
these proteins assist in forming the wide, elongated, contractile cells that are critical 
in supporting arterial vascular and regulating contractility and blood flow.  Reversion 
from a differentiated state includes initiating a decrease in stress fibers and higher 
order actin filaments, and adhesion complexes, to allow for increased migration, 
growth, and proliferation. Understanding smooth muscle plasticity is critical in 
understanding the progression of multiple cardiovascular disease states.  Aberrant 
regulation of smooth muscle differentiation is contributory to both atherosclerosis 
and neointimal hyperplasia.  In these diseases smooth muscle is induced to revert 
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from a differentiated state leading to an increase in smooth muscle migration, 
proliferation, and growth.  In atherosclerosis smooth muscle cells contribute to 
fibrous cap formation, foam cell generation, calcification, and other events 
contributory to disease progression [8-10].  The SMC contribution to neointimal 
hyperplasia is more overt with the majority of the lesion consisting of SMCs that 
originally populated the lumen by de-differentiating, migrating, and proliferating prior 
to re-differentiating to form a rigid occlusion.  
A better understanding of the processes that control SMC growth and 
differentiation will be very important for our understanding of vascular development 
as well as the role SMCs play in cardiovascular disease [11-13].  It has become 
clear that the key to understanding control of SMC differentiation is dependent upon 
understanding the transcriptional mechanisms that regulate expression of SMC 
specific marker genes including SM α-actin, SM myosin heavy chain (SM-MHC), 
SM-22, calponin, etc.  Unlike heart and skeletal muscle, which have master 
regulatory transcription factors (i.e. MyoD, Nkx2.5, Gata-4), SMCs do not have a 
master transcription factor that completely regulates their differentiation.  This lack of 
a master regulatory factor has hindered our understanding of the control of SMC 
differentiation by extra-cellular signals.  While poorly understood it has been 
established that SMC growth and differentiation are regulated by a complex array of 
local environmental cues including growth factors, contractile agonists, integrin-
matrix interactions, cell-cell interactions, inflammatory stimuli, and mechanical 
stresses (see [14, 15] for review).  However, few studies have identified the signaling 
SMC Differentiation Signaling 
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mechanisms by which these diverse pathways regulate SMC differentiation marker 
gene expression, and it is completely unknown whether signaling pathways 
converge to regulate differentiation or whether they exist as independent 
mechanisms.  Recent studies have shown that the processes of growth, migration, 
and differentiation are not mutually exclusive and that the same extrinsic cues that 
activate one process can stimulate another simultaneously [16-24]. This revelation 
both complicates our understanding of the control of SMC phenotype and 
underscores the importance of determining what intracellular proteins transmit these 
extrinsic cues.  
Despite these complexities, concerted efforts over the last several years have 
greatly increased our understanding of the complex transcriptional events regulating 
vascular SMC phenotype.  The upstream signals that regulate these newly 
discovered transcriptional regulation paradigms need further investigation.  This 
dissertation focuses on the upstream factors that regulate these transcriptional 
events including the cell surface and ligand initiated signaling via G-Protein Coupled 
Receptors (GPCRs).  The benefit of complete understanding of these pathways from 
ligand binding to transcriptional regulation is the application to the discovery of 
pharmacologic targets leading to clinically relevant therapies. 
Initial discoveries in the smooth muscle field implicated RhoA and Serum 
Response Factor (SRF) as a major regulator of SMC specific transcription.  SRF 
regulates SMC-specific transcription by binding to CArG (CC[A/T]6GG) cis elements 
The RhoA-MRTF Axis in SMC Transcription 
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that are found in the promoters of nearly all of the SMC differentiation marker genes 
[25-31]. Since SRF is ubiquitously expressed and also regulates other CArG-
containing genes including the early response genes, c-fos and egr-1, as well as 
several skeletal- and cardiac-specific genes [32-36], additional mechanisms must be 
present that regulate SRF activity in a SMC-specific manner. 
An important breakthrough came when Wang et al. and others identified the 
myocardin family of transcription factors that potentiate SMC differentiation specific 
regulation of SRF driven transcription [37-40].   The MRTFs were shown to be 
regulated in a RhoA dependent manner by our lab, the Wang lab, and others, thus 
forming the RhoA-MRTF axis (see Figure 1.2). In brief, conserved RPEL domains 
are found in the myocardin family members.  Actin has been shown to bind these 
RPEL domains in effect inhibiting myocardin family member nuclear localization and 
inhibiting SMC specific transcription.  RhoA-mediated increases in actin 
polymerization by its effectors mDia1/2, FHOD1/2, ROCK, and others depletes the 
cytoplasmic pools of G-actin by increasing actin polymerization causing the release 
of sequestered cytoplasmic myocardin family members allowing them to localize to 
the nucleus [41-44].  
The specification of SMC differentiation is regulated in part by the myocardin 
family of transcription factors (myocardin, Myocardin Related Transcription Factors 
A/B [MRTF-A/B]).   The importance of the myocardin family members in governing 
SMC regulation is exemplified in knockout experiments. The knockout of myocardin 
in mice resulted in embryonic lethality at E10.5 and was attributed to yolk sac and 
vascular defects [45]. The MRTF-B knock out embryos die at E13.5.  This lethality is  
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Figure 1.2. The RhoA-MRTF Axis in SMC Transcription.  RhoA integrates signals 
from a number of sources to regulate SMC specific transcription.  RhoA activation 
signals through its effectors to convert globular actin to filamentous actin.  Upon 
actin polymerization RPEL domain mediated binding of the MRTFs to globular actin 
is interrupted.  The MRTFs are then able to translocate to the nucleus and bind the 
CArG/SRF scaffold and drive SMC specific differentiation. 
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attributed to vascular defects arising in cells of the neural crest, one of the many 
originating tissues of differentiated SMC [46, 47].  The MRTF-A knock out is not 
lethal, possibly due to redundancy with myocardin and MRTF-B, but does exhibit a 
smooth muscle related phenotype.  Female mice that were null for MRTF-A are not 
able to express milk due to an inability to maintain differentiated mammary 
myoepithelial cells, a cell type comparable to smooth muscle [48]. Taken together 
the function of the myocardin family members are crucial in regulating vascular SMC 
phenotype from a number of origins.   
The regulatory mechanism that defines the RhoA-MRTF axis has been further 
refined in studies that pose a more specific role for nuclear specific regulation of 
SMC transcription.  These studies show that G-actin binding of MRTF-A is required 
for nuclear export and that the export, and not import, of MRTF-A is the limiting step 
that governs the MRTF-A mediated transcription of CArG containing SMC genes.  
Importantly Vartiainen et al. show that globular actin associated with MRTF-A did not 
prevent transcriptional complex binding, but it did inhibit transcriptional activity [49, 
50].  
The Rho family of GTPases are a major branch of the Ras (Rat Sarcoma) 
superfamily which comprises over 150 mammalian genes.  The Rho family genes 
are identified by the presence of a Rho specific insert between the G4 and G5 boxes 
that are involved in the binding of Rho specific regulators and effectors [51]. The 
small GTPases range from 20-40 kDa with few exceptions [52].  They all have a 
The Rho family of GTPases 
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nucleotide binding pocket regulated by two highly conserved switch regions that 
change the overall protein conformation upon nucleotide binding.   This 
conformational shift modulates the signaling capabilities of the protein.  Additionally 
most Rho GTPases are localized to membranes by post-translational farnesylation 
or geranylgeranylation of a C-terminal cystine residue.  Rho GTPase membrane 
localization is thought to serve as an additional level of activation control [53, 54].  
The Rho GTPases have been linked to the regulation of vesicle trafficking, 
cytokinesis, migration,  cell survival, proliferation, differentiation, gene expression 
and many other cytoskeletal dependent and independent processes [55-57].  Since 
the gene for Ras homologous (Rho) was first discovered in the mollusk Aplysia in 
1985 [58], at least 22 human genes of the Rho family have been described.  The 
majority of investigation has focused on three distinct members RhoA, Rac1, and 
cdc42.  While these GTPases have been shown to play vastly different roles in 
regulating cellular structure and function classically stress fiber, lamellipodia, and 
filopodia respectively, the molecular switching that initiates signaling to effector 
proteins remains remarkably similar in nearly all Rho family GTPases.  Rho proteins 
cycle on and off by toggling between GTP and GDP bound states.  When nucleotide 
free, Rho proteins have a similar affinity for either GDP or GTP nucleotides.  
However, the ratio of GTP to GDP in the cell results in a higher rate of GTP binding.  
When GTP bound, Rho proteins are in an active state and signal through their 
effector proteins responsible for conducting their downstream signaling.  Hydrolysis 
of GTP to GDP molecules, whether occurring slowly through intrinsic hydrolysis or 
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encouraged by GTPase Activating Proteins (GAPs), inactivates Rho (see Figure 
1.3). 
There are three classes of proteins that regulate Rho GTPase activity.  The 
Rho Guanine nucleotide Exchange Factors (RhoGEFs) activate Rho GTPases by 
promoting the exchange of GDP for GTP [59]. Conversely GTPase activating 
proteins or Rho GAPs decrease Rho activity by promoting hydrolysis of GTP to 
GDP.  Lastly another negative regulator of Rho proteins are a protein class known 
as GDP dissociation inhibitors (Rho GDIs). These proteins sequester Rho in the 
cytoplasm and prevent nucleotide dissociation, in effect inactivating Rho [60].  In 
addition to the canonical understanding of GEF, GAP, GDI mediated Rho GTPase 
regulation there is emerging evidence (much of it specific to RhoA), that subcellular 
localization of Rho is an important, and oft-employed, method to control Rho 
signaling.  Previously it was assumed that cytosolic Rho was inactive and that 
activated RhoA was localized exclusively to the plasma membrane.  More recent 
evidence has challenged this view of RhoA localization.  For instance some elegant 
biosensor experiments have shown that there are distinct fractions of RhoA found 
throughout the cell.  These researchers document active RhoA concentrations in a 
2µm band at the edge of protrusions, in the trailing edge during robust contractile 
events, and a discrete but inactive perinuclear pool [61, 62]. Despite the power and 
resolution of these Rho GTPase biosensors their inability to enter the nucleus has 
left questions concerning RhoA activity in the nucleus.  Several GEFs including 
Net1, LARG, and PRG, and have been shown to localize to the nucleus but  
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Figure 1.3. RhoA GTPase Regulation. Small RhoA GTPases are considered 
molecular switches.  This switching is regulated by a number of proteins that fit three 
classifications.  GEF activate Rho by increasing RhoGTP binding.  GAPs inactivate 
RhoA by increasing intrinsic GTP hydrolysis to GDP and GDIs bind and sequester 
RhoA as well as slow the rate of GDP dissociation.   
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evidence that they are activating RhoA there remains elusive [63, 64]. These data 
and others highlight the fact that our current understanding of RhoA activation and 
signaling is incomplete, and the field would benefit by a more thorough 
understanding of the spatial activation of RhoA in a number of cellular contexts.  
As previously discussed, the activation of small G proteins is achieved by 
proteins categorized as Guanine Exchange Factors or GEFs (see [59] for review).   
The first mammalian RhoGEF was found in Diffuse B-cell-Lymphoma cells, (Dbl) 
and shown to contribute to neoplastic transformation.  Homology to the active site of 
this gene defines most but not all RhoGEFs [65, 66]. To date there are over 80 
identified Human Rho GEFs, curiously around four times more than the Rho 
GTPases they are designed to activate.  The majority of these GEFs share a Dbl 
homology (DH) domain that confers GEF activity by binding the GTPase and 
causing the dissociation of GDP and stabilizing the nucleotide free state to allow 
binding of stoichiometrically dominant GTP.   The tandem pleckstrin homology (PH) 
domains are thought to regulate GEF activity by promoting membrane localization 
and other, less well described, allosteric mechanisms [67].  The individual specificity 
of GEFs for specific small GTPases is quite variable and is thought to be determined 
by variations in the DH domains in combination with variations within the switch 
regions of the small GTPase where the GEFs have been shown to bind [59, 68-70].  
GEF Signaling in Mammalian Systems 
The GEF family is divided into many different sub-families based upon the 
presence of additional regulatory domains (i.e. SH2, IgG-like, FERM) and very little 
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is known about how individual GEFs are regulated.  What is apparent however is 
that, given the number of GEFs in the genome, and the number of diseases they are 
involved in, understanding exactly how they function will be important [63].  The 
diversity seen in expression and composition of RhoGEFs is also reflected in their 
GTPase specificity.  Some GEFs, have been shown to activate virtually every Rho 
GTPase they interact with while others are specific to only RhoA, Rac1, cdc42 [59, 
71].  The pathways investigated in this dissertation are, in general, RhoA-dependent.  
One subfamily of RhoGEFs known as the Regulator of G Protein Signaling (RGS) 
RhoGEFs have repeatedly shown a specificity for RhoA, thus, a major focus of this 
dissertation will be the study of the signaling properties that govern RGS RhoGEF 
function. 
There are three RGS RhoGEFs found in humans: P115 RhoGEF (P115), 
PDZ RhoGEF (PRG) and Leukemia Associated RhoGEF (LARG) (see Figure 1.4). 
All three RGS RhoGEFs specifically activate RhoA but not the closely-related small 
GTPases, Rac, and cdc42 [72].  Phylogenetic analysis has revealed that the three 
RGS RhoGEFs found in humans diverged relatively early in GEF evolutoion.  The 
specific combination of an RGS like domain coupled with a DH/PH domain is 
conserved as far back as C. elegans in the protein identified as rhgf-1[73].  The 
drosophila ortholog, which approximates the mammalian RGS RhoGEFs, 
DRhoGEF2 is essential for the invagination of mesodermal and endodermal 
primoridal during gastrulation [74].  These observations are instructive of the ancient  
Structure and Function of the RGS RhoGEFs 
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Figure 1.4. Size and Modular structure of the RGS RhoGEFs.  PDZ (PSD-95 
Discs-large ZO-1) Domain: Some PDZs have been shown to bind C-terminal 
polypeptides; others appear to bind internal (non-C-terminal) polypeptides.  RGS 
(Regulator of G Protein Signaling) Domain: RGS family members are GTPase-
activating proteins for heterotrimeric G-protein α-subunits that promote GTP 
hydrolysis by the α subunit of heterotrimeric G proteins, thereby inactivating the G 
protein and rapidly switching off G protein-coupled receptor signaling pathways.  DH 
(Dbl Homology) Domain: About 200 residues shown to encode GEF activity 
specific for a number of Rho family members.  PH (Pleckstrin Homology) Domain:  
About 100 residues that may have multiple functions or different functions in different 
proteins, including signal transduction, membrane anchoring, and protein-protein 
interaction. LARG and PRG share 29% amino acid identity and 62% similarity. 
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importance of this family of RhoGEFs even in comparison to RhoGEFs of other 
domain structure.  The domains they all share in common are a RGS domain and a 
tandem DH/PH domain.  Of the three, PRG and LARG share the closest similarity 
and both have conserved PDZ domains.  They are more similar in size (1544 and 
1522 AA, respectively) than the smaller P115 (913 AA).  Additionally it should be 
noted that methods of activating the RGS RhoGEFs, other than Gα12 and Gα13, have 
been observed.  For instance the PDZ domain of LARG and PRG is thought to 
interact with plexins to regulate of growth cone morphology and other RhoA 
dependent events [75-79]. 
The addition of an RGS domain to a GEF in order to make one functional 
protein is intriguing in design.  This design bridges signaling between the 
intracellular signaling of G protein coupled receptors and small Rho GTPases. In 
brief, upon activation GPCRs allosterically activate Gα subunits by exchanging a 
molecule of GDP for GTP. The RGS domain, which itself is found in over 20 human 
proteins, acts allosterically to stabilize the transition state of the GTP binding pocket 
of heterotrimeric Gα subunits, in effect increasing the GTPase activity of the 
proteins, hydrolyzing the GTP nucleotide to GDP and inactivating the G protein.  
Thus, the addition of an RGS domain to a GEF creates a protein with a duality of 
purpose, to increase GTP hydrolysis of G proteins in order to activate small G 
proteins. The RGS domain activity of the RGS RhoGEFs is confined mainly to Gα12 
and Gα13 subunits [80-82]. The discovery that RGS RhoGEFs are activated by the 
Gα12 /13 subunits of G protein heterotrimers implicates RGS RhoGEF activity in 
response to GPCR. The reason for this is that Gα12/13 are found bound to the 
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cytoplasmic side of seven trans-membrane proteins.  However, there is some 
controversy about preference of some GEFs for Gα12 over Gα13 and vice versa.  It 
should be noted that drosophila and mice only carry one ortholog of Gα12 and Gα 13 
(named Gα12, or concertina in drosophila). For a more in depth look at Gα12/13 
signaling variations (see [82-85] for review). 
While often categorized as ubiquitous, LARG expression in the lung and GI 
tract of the mouse was specific for the SMC layers in those organs [86, 87].  
Regardless we have shown that all three RGS RhoGEFs are expressed in rat aortic 
SMC (see Figure 1.5). There have been some KO studies conducted on these 
individual GEFs.  The P115 KO mouse showed no lethality but numerous neutrophil 
defects associated with adhesion, migration, and other actin dependent processes 
were observed [88].  There are no reports of a global PRG KO studies but PRG KD 
dHL60 cells were observed to show multiple pseudopods or long tails and to migrate 
with reduced speed and persistence [77].  The Offermanns lab has generated a 
LARG KO mouse but it has not been fully characterized.  There has been no 
reported lethality but it has been shown that, unlike wild type mice, the LARG KO 
mice did not develop hypertension in response to DOCA-salt treatment indicating a 
protective role in the normal pathological hypertensive response[89]. 
The individual signaling specificity of the RGS RhoGEFs is still unclear.  
Though poorly understood, an emerging paradigm with respect to RGS RhoGEF 
function, is the regulation of migration, adhesion and differentiation, all in a Rho 
dependent manner in response to GPCR signaling.  A family of proteins that link 
GPCR signaling to events in the vasculature known to regulate the pathogenesis of  
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Figure 1.5.  Semi-quantitative RT-PCR Expression Profile for LARG, P115 
RhoGEF, and PRG.  RNA was isolated from mouse tissues and cell lysates in order 
to construct cDNA transcripts. Left to right the following tissues or cell types were 
treated: heart, aorta, Cos7, A7R5, 10T1/2, and primary rat aortic SMCs.  LARG, 
P115 RhoGEF, and PRG were all expressed at high levels in the aorta, 10T1/2, and 
rat aortic smooth muscle cells. 
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multiple cardiovascular disease states is of immediate therapeutic interest, and a 
subject of intense study in this dissertation.   
Sphingosine 1-phosphate (S1P) is a hydrophobic zwitterionic lyso-
phospholipid that fits into the class of molecules known as sphingolipids.  
Sphingolipids were studied and named by J.L.W. Thuduichum in 1884 [90].  
Etymologically the choice “sphingolipid” was made as an allusion to the mythical 
Greek Sphinx.  Despite the efforts of modern researchers, lipid signaling remains 
enigmatic in many respects.  A review of the literature surrounding S1P signaling 
often ends with models and theories about system wide S1P signaling with names 
like “the sphingolipid rheostat” or the “S1P paradox” indicating the difficulty, 
complexity, and elusiveness of fully explaining how sphingolipid signaling works.  
This is not to say that progress hasn’t been made but it is fair to say that much of the 
enigma of S1P signaling remains unsolved [91].  Many of the goals of this 
dissertation have been to investigate and understand the complexities of S1P 
signaling in smooth muscle. 
S1P Metabolism and Concentration 
 S1P is found at very high concentrations in human serum ranging between .5 
to 1 µmol/L or more.  Despite these concentrations there is a steep gradient between 
intracellular and extracellular concentrations of S1P [91].  S1P has important 
biological functions in both intracellular and extracellular compartments [92, 93].  
S1P metabolism is well understood.  S1P originates from the common membrane 
component, sphingomyelin which is metabolized to its active form by 
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sphingomyelinase to generate two components phosphorylcholine and ceramide.  
Ceramide is broken down by ceramidase into sphingosine and finally 
phosphorylated by one of two known sphingosine kinases (SphK1 or 2).  S1P can be 
reversibly cleaved by Sphingosine Phosphatase or irreversibly degraded by 
S1Plyase into phosphatidylethanoliamine and hexadecanal (see Figure1.6).   
S1P signals through a family of high affinity GPCRs named S1PR1-5.  These 
receptors, formerly known as Edg receptors 1, 5, 3, 6, and 8, respectively, grant S1P 
the ability to signal in a multitude of pathways.  Heterotrimeric G protein binding, 
receptor expression, affinity, and internalization are all methods utilized by these 
receptors to govern S1P mediated signaling. 
S1P Receptor Subtypes  
 Four of the five S1P receptor knockouts have been made and characterized 
to varying degrees.  The S1PR1 knockout is the only one that alone results in 
embryonic lethality.  This lethality occurs between E12.5 and E14.5 and is attributed 
to EC mediated vascular maturation defects. The authors show that vasculogenesis 
and angiogenesis occurred without disruption, but that the deficiency in smooth 
muscle cell investment of the vasculature causes the observed lethality through 
systemic hemorrhage [94].  From a pharmacology standpoint this was a seminal 
finding since it was the first to show that a GPCR was required for vascular 
maturation and that S1P signaling was essential in development.    It is also of note 
that S1PR1 has been shown to be important in limb development as well as in 
lymphocyte trafficking [95-98].  
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Figure 1.6 Sphingosine 1-Phosphate Metabolism.   S1P can be generated from 
the de-novo generation of ceramide or from the ceramide that occurs as the 
sphingolipid biosynthetic pathway.  In the sphingolipid biosynthetic pathway 
sphingomyelinase cleaved sphingomyelin to generate ceramide which is cleaved by 
ceramidase to generate sphingosine, which is phosphorylated by one of two 
sphingosine kinases to generate S1P.  S1P can be de-phosphorylated by S1P 
phosphatase or irreversibly cleaved into phosphatidylethanolamine and hexadecanal 
by S1P lyase.  Complementary synthases can create Ceramide and Sphingomyelin 
from their metabolite products. 
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The phenotype of the S1PR2 knock out is much more elusive and less well 
characterized.  Three groups have made S1PR2 -/- mice and observed some 
similar, but many different effects.  The Lee lab were the first to KO S1PR2 and 
observed no embryonic lethality but estimated seizures in 100% of the mice between 
weeks 3 and 7, and that approximately 14% of the null mice die due to seizures [99].  
The Chun lab independently knocked out the S1PR2 gene and, in their hands, they 
found little to no observable differences in the S1PR2 KO mice, but did find that the 
S1PR2/3 double nulls had reduced litter size and marked lethality thorough infancy 
[100].  The conclusions reached from the Chun lab were that the S1PR2/3 work 
independently regulating the Rho and PLC/Ca2+ pathways respectively but that both 
of these receptors and pathways are important in development.   
The Proia lab, that did the original S1PR1 knockout and characterization, 
went on to knock out the S1PR2 and 3 receptors as well.  In their hands they show 
that the S1PR1/2 double null and the S1PR1/2/3 triple null showed substantially 
more severe vascular phenotypes than the S1PR1 KO and that while the S1PR2 or 
S1PR3 KO mice showed little or no lethality alone the S1PR2/3 double nulls had 
partial embryonic lethality.  This particular line of S1PR2 null mice has been further 
investigated and a number of vascular pathologies have been observed.  Sokura et 
al. have shown that when S1PR2 -\- neonates were exposed to ischemia-driven 
retinopathy the normal pathologic neovascularization observed was suppressed 
[101].  Kono et al. reported a deafness phenotype arising from multiple inner ear 
pathologies, the earliest of which arises in the stria vascularis, a compartment that 
harbors the main vasculature of the inner ear [102]. Shimizu et al. also showed that 
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after injury neointimal hyperplasia is greatly increased in S1PR2 -\- mice and that 
S1P increased RhoA activity in wt but not S1PR2 null mice [103].  This group went 
on to show that S1PR2 regulates SM α-Actin and SM22 expression in smooth 
muscle and that S1PR2 regulates SM α-Actin after vascular injury [104].   The S1P 
receptors 4 and 5 have a much more restrictive expression pattern limited to the 
lymphoid and lung for the former and brain, skin, and spleen for the latter.  S1PR5 
has been knocked out but there was no observed phenotype and S1PR4 has been a 
target of little investigation.  While a full dissection of S1P receptor function involves 
discussion of the 4 and 5 receptors, as they are not expressed in smooth muscle 
containing tissues, their effects are not germane to this dissertation [105, 106].  
S1P has also been shown to regulate a number of cellular processes 
intracellularly as a second messenger.   First, S1P itself can be synthesized through 
one of the aforementioned methods leading to an increase in intracellular S1P 
levels. It has been shown that S1P levels can modulate intracellular Ca2+ 
concentrations suggesting that SphK mediated production of intracellular S1P 
without any ligand-induced signaling can activate intracellular Ca2+ stores [107, 
108].  S1P also signals intracellularly to suppress apoptosis. This conclusion was 
reached when intracellular S1P was observed to prevent the appearance of 
intranucleosomal DNA fragmentation and associated apoptotic morphological 
changes [109].  Prolonged inhibition of proliferative responses in lymphocytes is an 
example of intracellular S1P ligand to S1PR1 receptor signaling on the nuclear 
membrane [92].   
Heterotrimeric Subunit Coupling 
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The most well studied property of the S1P receptors, and possibly all GPCRs, 
are the intracellular G protein binding properties.  The cytoplasmic side of GPCRs 
are bound to heterotrimeric G proteins consisting of a G α, β, and γ subunits.  While 
G β and γ are known to regulate some signaling little is known about them and it is 
generally understood that the majority of signaling transduced by GPCR agonist 
binding is carried out by the Gα subunit. There are, at present, 20 known Gα 
subunits separated into four main classifications including Gαi, s, q, and 12/13.  While it 
is not completely understood, and the individual binding affinities lack fidelity, it has 
been shown that S1P receptor subtypes are bound to specific Gα subuinits.  S1PR1 
is thought to bind primarily to Gαi, S1PR2 and 3 have been shown to bind to Gαi, q, 
and 12/13 and S1PR4 and 5 have been shown to bind Gαi and Gα12/13.  Gα subunit 
binding is critical as it regulates the majority of intercellular signaling that occurs 
upon ligand binding.  Gαq is thought to signal primarily by activating phospholipase C 
(PLC).  Gαi inhibits the production of cAMP from ATP, Gαs conversely activates the 
cAMP pathway eventually activating PKA and its associated downstream targets.  
Gα12/13 are very important in the regulation of cytoskeletal remodeling most notably 
through their activation of RhoA.  Because of their known association with RhoA 
activation the Gα12/13 subunits are closely studied throughout this dissertation. It 
should be noted that Gαq can also couple to S1PR2 and other S1P receptor 
subtypes and has been shown to activate RhoA [110-112].   
 In addition to S1P intracellular signaling, receptor subtype specificity, and Gα 
subunit selectivity, receptor expression can modulate S1P signaling as well.  In 2007 
Grabski et al showed that S1PR2 regulated neointimal formation in injured mouse 
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carotid arteries.  They went on to show that the S1PR2 regulated the migratory 
response of the SMC population comprising the lesion but stopped short of a 
mechanism [104]. Shortly after Wamhoff et al were able to show that arterial injured 
SMC phenotype was largely controlled by acute changes in S1P receptor subtype 
expression.  They show that S1PR1 is significantly upregulated 24 and 72 hours 
post injury while conversely, S1PR2 is down regulated during that time.  Most 
interestingly S1PR2 is significantly upregulated 10 days post injury before all of the 
S1PR expression levels reach equilibrium 14 days after injury.  When these 
expression variations are juxtaposed against a timeline of lesion formation the 
signals to regulate dedifferentiation, migration, proliferation, and differentiation can 
largely be explained by the observed changes in S1P mediated signals sent in S1PR 
specific ways [113].   
Receptor internalization after extracellular ligand binding, while previously 
considered an endpoint in signaling, has recently been suggested to be the 
beginning of a number of intracellular signaling events.  In general GPCR kinases 
(GRKs) and β-arrestins bind activated receptors and promote their internalization, a 
process referred to as desensitization [114].  Receptors can then be recycled back 
to the plasma membrane in a process known as resensitization or transported to 
lysosomes for degradation.  Some GPCRs have even been shown to translocate to 
the nucleus [115].  There is an intriguing body of evidence that shows S1PR1 and 
possibly S1PR2 internalize in response to phosphorylation while S1PR3 does 
internalize but independently of phosphorylation [116, 117].  It is clear that receptor 
trafficking can differ between receptor subtype. Also that this has functional 
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implications on S1P dependent signaling that should be considered in any analysis 
of S1P dependent signaling especially when pharmacologically modified or synthetic 
ligands are used. 
 The goal of this dissertation is to improve our understanding of S1P mediated 
RhoA signaling in SMC.  S1P based therapies are just beginning to be utilized in the 
clinic and represent the next generation of weapons to combat CVD. Deutschman et 
al have shown that S1P serum levels can be used as an accurate predictor of both 
the occurrence and severity of coronary stenosis [118]. According to the 2009 AHA 
update there were 1.3 million angioplasties and 448,000 Coronary Artery Bypass 
Grafts (CABGs) performed in the U.S. alone. Discoveries made and conclusions that 
can be drawn from this body of work have direct implications toward the 
development of pharmacological based therapies to combat the morbidity and 
mortality associated with CVD.  These pharmacologic agents could be used in lieu 
of, or in conjunction with, the surgical interventions currently employed to treat CVD.  
Obviously the regulation of S1P-mediated signaling is complex and multifactorial. 
The hypotheses put forth and the experiments employed through the body of this 
dissertation provide smooth muscle specific insights to the behavior, and by 
extension possible manipulations, of SMC in order to build, maintain, and restore 
healthy functional vasculature.    
Dissertation Summary 
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Objective: The goals of this study were to identify the signaling pathway by which 
S1P activates RhoA in SMC and to evaluate the contribution of this pathway to the 
regulation of SMC phenotype. 
Abstract   
Methods and Results: Using a combination of receptor-specific agonists and 
antagonists we identified S1PR2 as the major S1P receptor sub-type that regulates 
SMC differentiation marker gene expression. Based upon the known coupling 
properties of S1PR2 and our demonstration that over-expression of Gα12 or Gα13 
increased SMC specific promoter activity, we next tested whether the effects of S1P 
in SMC were mediated by the RGS-RhoGEFs (LARG, PRG, P115).  Although each 
of the RGS-RhoGEFs enhanced actin polymerization, MRTF-A nuclear localization, 
and SMC-specific promoter activity when over-expressed in 10T1/2 cells, LARG 
exhibited the most robust effect and was the only RGS-RhoGEF activated by S1P in 
SMC. Importantly, siRNA-mediated depletion of LARG significantly inhibited the 
activation of RhoA and SMC differentiation marker gene expression by S1P. 
Knockdown of LARG had no effect on SMC proliferation, but promoted SMC 
migration as measured by scratch wound and transwell assays.  
Conclusion: These data indicate that S1PR2-dependent activation of RhoA in SMC 
is mediated by LARG and that this signaling mechanism promotes the differentiated 
SMC phenotype. 
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Smooth muscle cell (SMC) differentiation is critical during vascular 
development, and alterations in SMC phenotype contribute to a number of 
cardiovascular pathologies including atherosclerosis, hypertension, and restenosis 
[13]. Although our understanding of SMC differentiation has been complicated by the 
plasticity of this cell-type and the fact that SMC originate from multiple locations 
within the embryo [4], the transcription mechanisms involved are starting to become 
clear. Extensive evidence indicates that Serum Response Factor (SRF) regulates 
nearly all of the SMC differentiation marker genes by binding to CArG cis elements 
within their promoters [13].  The discovery of the SRF co-factor, myocardin, was an 
extremely important advance because this cardiac and smooth muscle selective 
transcription factor strongly activates SMC-specific transcription in many cell-types 
and is required for SMC differentiation in the developing aorta [40]. Two Myocardin-
Related Transcription Factors, MRTF-A and MRTF-B, have also been identified. 
Although expressed more widely than myocardin [119], studies have demonstrated 
that the MRTFs up-regulate SMC-specific transcription and are required for 
endogenous SMC differentiation marker gene expression in at least some SMC sub-
sets [120, 121].   Importantly, genetic disruption of MRTF-B in the mouse resulted in 
defective SMC differentiation of the cardiac neural crest cells that populate the 
brachial arches [46, 47], while loss of MRTF-A inhibited the expression of SM α-actin 
that occurs in mammary myoepithelial cells during lactation  [48, 122]. 
Introduction 
The identification of the signaling mechanisms that regulate the myocardin 
factors will be important for our understanding of the control of SMC phenotype. The 
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Treisman laboratory was the first to demonstrate that MRTF nuclear localization is 
regulated by the small GTPase, RhoA [123], and we and others have shown that 
RhoA/MRTF signaling is a critical determinant of SMC-specific transcription [41, 44, 
120, 121]. Furthermore, RhoA activity was shown to be required for the induction of 
SMC differentiation marker gene expression by angiotensin II, TGF-β, intracellular 
calcium, and mechanical stretch suggesting that this pathway plays an integral role 
in the regulation of SMC phenotype [124-128].  
RhoA activity is tightly regulated by GTPase Activating Proteins (GAPs) that 
facilitate RhoA’s intrinsic GTPase activity (inhibiting RhoA), Guanine Exchange 
Factors (GEFs) that facilitate exchange of GDP for GTP (activating RhoA), and Rho 
GDP-dissociation inhibitors (RhoGDIs) that sequester RhoA into an inactive fraction. 
However, the major regulators of RhoA activity in SMC are not completely clear, and 
even less is known about the signaling mechanisms by which these proteins are 
activated.  We were the first to demonstrate that the lipid agonist, sphingosine 1-
phosphate (S1P), up-regulates SMC-specific gene expression by activating RhoA 
[120]. The goal of the current study was to identify the signaling pathway that 
mediates the effects of S1P on RhoA in SMC and to evaluate the contribution of this 
pathway to the regulation of SMC phenotype.  
Plasmids and Reagents - S1P, FTY-720, SEW2871, and JTE-013 were purchased 
from Cayman chemical. LARG, PRG, and P115 cDNAs were kind gifts from Dr. T. 
Kozasa (University of Tokyo).  Gα12 and Gα13 cDNAs were kind gifts from Dr. P. 
Materials and Methods  
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Gierschik (Ulm University, Germany). The Gαq cDNA was a kind gift from Dr. G. 
Johnson (University of North Carolina, Chapel Hill, NC). All cDNAs were sub-cloned 
into pcDNA 3.1. Antibodies to LARG and PRG were kind gifts of Dr. Keith Burridge 
(University of North Carolina, Chapel Hill, NC). The P115RhoGEF Ab was 
purchased from Santa Cruz. 
Transient Transfections and Reporter Gene Assays - The 10T1/2 and SMC cell 
cultures, transient transfections, and promoter luciferase assays have been 
previously described [44, 120]. Statistical comparisons between groups were made 
using the Student's t test with statistical significance accepted at p<0.05. 
GST G17A Pull-downs - GST-Rho(G17A) was a kind gift of Dr. K. Burridge and pull-
downs were performed as previously described [129].  In brief, SMCs were plated 
and starved for 24 hours and then treated with S1P (10µM) or 10% serum for 3.5 or 
9 minutes.  Protein lysates were incubated with 20µg GST-Rho(G17A) beads at 4 ˚C 
for 3 hours. Complexes were washed 3X in lysis buffer prior to analysis by Western 
blot. 
Immunoflourescence -  10T1/2 or primary SMCs were plated and transfected in 4-
well chamber slides, maintained in 10% serum overnight. Cells transfected with 
GFP-MRTF-A were serum-starved for 16 h Cells were fixed in 3.7% 
paraformaldehyde/PBS for 20 min and permeabilized in 0.5% Triton X-100/PBS for 
3-4 min. Cells were then incubated with M2 anti-flag (1:500)(Sigma) in 20% Goat 
Serum / 3% BSA in PBS for 2 hours.    Texas Red, FITC (Jackson 
ImmunoResearch), conjugated secondary antibodies were used at (1:1000) while 
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AlexaFluor 546 Phalloidin (Molecular Probes) and DAPI (Molecular Probes) were 
used at 1:100 and 1nM, respectively 
siRNA Knockdowns - siRNA oligos were purchased from Invitrogen and 
transfections were performed using the Dharmafect transfection reagent as per 
protocol. RGS-RhoGEF knockdown was confirmed in all experiments by western 
blotting.  
RhoA Activity Assays - To measure RhoA activity in our RGS RhoGEF KD cells we 
used the luminescence based G-LISA RhoA activation assay kit by Cytoskeleton inc. 
as per protocol.  In brief following 72 hours KD Cells were starved for 24 hours and 
treated with S1P for 12 minutes, lysed, cleared, equalized and measured for RhoA 
activity.  Concurrent western blots were performed to ensure adequate KD. 
Quantitative RTPCR - Briefly primary SMCs were transfected with 19nt siRNA oligos 
to deplete LARG expression (identical plates were processed for western blots to 
confirm the level of KD). Trizol was used to achieve RNA extraction and purification 
and RNAs for control and LARG KD cells were combined with primer and probe sets 
specific to mouse SM22 and SM α-actin.  RNA levels of each SMC marker were 
normalized to an internal 18S control during analysis. 
QRTPCR- Primer sets used were as follows 
SM22 Forward- TGCAGTGTGGCCCTGATGT 
SM22 Reverse- TGCTCAGAATCACACCATTCT 
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SM α-Actin Forward- CGCTGTCAGGAACCCTGAGA 
SM α-Actin Reverse- CGAAGCCGGCCTTACAGAG 
Transwell Assays- In brief SMCs were transfected with control or LARG specific 
siRNA.  After 72 hours of KD cells were split, counted, and equalized. Three 
thousand cells were plated on the tops of fibronectin coated transwells (8µm pore 
size) in a 24 well format.  Cells were allowed to migrate toward DMEM F-12  + 10% 
Serum in the bottom chamber for 18 hours prior to processing. Chambers were 
rinsed with PBS, cells were removed from the top chamber by scraping with a cotton 
swab, and the remaining cells (in the bottom chamber) were fixed in 4% 
paraformaldehyde for 20 min. Cells that had migrated to the bottom chamber were 
visualized by crystal violet staining for 4 hours. Data represent the total number of 
cells in 12 separate fields for each condition through three separate experiments. 
Migration Assays - For wound healing assays, confluent cultures of control and 
LARG knockdown SMC were scraped with a P200 tip and then placed on an 
inverted microscope equipped with a heated, humidified, and O2/CO2 perfused 
stage. Pictures taken every 3.5 minutes for 9 hours were assembled into movies 
using Quicktime.  At the end of each experiment cell lysates were subjected to 
western blot to ensure LARG knockdown.  
Wound Healing Assay Equipment Specifics-   Equipment and instruction was 
provided by Dr. C. Robert Bagnell, Jr., Ph.D. Professor and Director of the 
Microscopy Services Laboratory at UNC Chapel Hill.   
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Olympus IX70 Live Cell Inverted Fluorescence Microscope Description: 
 The Olympus IX70 is an inverted microscope equipped for bright field, phase 
contrast, and epi-fluorescence. It is enclosed within an environmental chamber 
capable of controlling both temperature and relative humidity. It is equipped with a 
Uniblitz shutter on the transmitted light system and a Ludl stepper moror filter/shutter 
controller on the epifluorescence system, a BioPrecision motorized stage with linear 
encoders and motorized focus with servo feedback all controlled by a LEP MAC5000 
controller. Image capture is by a Hamatsu ORCA CCD camera. The system is 
controlled by an Apple IMAC computer using Improvision’s Open Lab software. 
Carbon dioxide supply is provided from a 100% CO2 tank connected to a flow meter 
and controlled by a precision needle valve. CO2 is passed through a water column 
and delivered through tubing to custom-made tabulated lids that match various cell 
culture dish configurations. 
siRNA KD-All siRNA oligos were designed through, and purchased from, Invitrogen.  
Transfection of 21NT siRNA oligos was accomplished with Dharmafect transfection 
reagent as per protocol. A cocktail of two separate siRNA oligos was used for each 
GEF. 
siRNA KD-  RGS RhoGEF KD Sequences 5’3’ 
LARG1-AAACCAAAUGUAUAGAGCUTT 
LARG2-CCCACUUGCUGAUUCUGAATT  
P1151-AUCUUCUGAGUUCGCCUCCTT  
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P1152-UUAGAUGUCGACAAUCUGGTT 
PRG1-GGGAGAUUCUACACCUGAATT  
PRG2-GCAACUGACCGUCAAGCUUTT 
BRDU Incorporation -SMCs were plated in 4 well chamber slides and transfected as 
per protocol with LARG or NTC siRNA.  After 48 hours transfection BrdU [10µm] was 
added for 18hrs.  After BrdU incorporation plates were fixed in 3.7% 
paraformaldehyde/PBS for 20 min, treated with 2M HCL for 1hr, washed with 0.1M 
borate, permeabilized and incubated with anti-BrdU 1:50 (Abcam cat# ab-9557 ) in 
20% goat serum 
Results 
 As shown in figure 2.1, treatment of serum-starved mouse SMC with S1P 
strongly up-regulated the expression of multiple SMC differentiation marker genes 
including smooth muscle myosin heavy chain (SM MHC), SM22, SM α-actin and 
calponin. These results are in excellent agreement with previous studies from our 
lab and others [104, 113, 120]. S1P signals through a family of G-protein coupled 
receptors (S1PR1-5) [130]. Because S1P receptor expression levels and coupling 
properties can vary significantly, it is often difficult to identify the receptor sub-type 
that mediates a specific S1P-dependent response. RT PCR analysis revealed that 
our aortic SMC cultures express S1PR1, S1PR2, S1PR3, and low levels of S1PR5 
(data not shown). To help determine which of these receptor subtypes was  
S1P signals through S1PR2 to activate SMC differentiation marker gene expression 
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Figure 2.1.  S1P stimulated SMC differentiation marker gene expression 
through S1PR2.  A.  Mouse aortic SMC were serum-starved for 24h and then 
treated with S1P (10µM) for 24 hours. Cell lysates were separated on an SDS-page 
gel, transferred, to nitrocellulose and probed with antibodies to the indicated SMC 
differentiation marker genes.  B. Western Blots were performed on SMCs that were 
serum-starved and then treated for with S1P [10µm], SEW2871 [5µm] (stimulates 
only S1PR1), or FTY-720 [10µm] (stimulates all S1P receptors except S1PR2).  
SMC marker expression represents 24 hours agonist treatment.  MAPK activation 
control represent 12.5 minute agonist treatment C . Western blots were performed 
on SMC treated with S1P for 24 hours +/- pre-treatment with JTE-013. D. 10T1/2 
cells transfected with the indicated promoter luciferase construct were treated with 
S1P +/- pretreatment with the S1PR2 antagonist, JTE-013. Luciferase activity was 
measured 24 after treatment and is expressed relative to untreated cells. * p < 0.05 
vs S1P-treated in the absence of JTE-013.   
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responsible for activating SMC-specific transcription, we utilized several receptor 
sub-type specific agonists and antagonists. SMC differentiation marker gene 
expression in SMC was not enhanced by SEW2871, an S1PR1-specific agonist, or 
FTY720, an S1P agonist that activates all S1P receptors but S1PR2 (Figure 2.1b). 
However, as expected by the known coupling patterns of the S1P receptors (see 
below), these agonists did activate MAPK. To examine the role of S1PR2 more 
directly, we pre-treated SMC cells with the S1PR2-specific antagonist, JTE-013. 
Importantly, JTE-013 inhibited the effects of S1P on SM α-actin and SM22 protein 
expression in SMC (Figure 2.1c). To determine whether these effects were mediated 
transcriptionally we also tested JTE-013 on S1P-dependent SMC-specific promoter 
activity in multi-potential 10T1/2 cells. This SMC precursor line is frequently used to 
study SMC-specific gene activation [131-134] and our RT PCR analyses indicated 
that 10T1/2 cells express all 5 S1P receptors (data not shown). As shown in figure 
2.1d JTE-013 dose-dependently inhibited SM22 and SM a-actin promoter activity. 
JTE-013 did not affect the expression of housekeeping genes or the activity of a 
minimal thymidine kinase promoter in these studies.   
The G-protein-dependent signaling pathways activated by S1PR1-3 have 
been fairly well-characterized in a number of heterologous cell culture systems (see 
[130] for review). S1PR1 couples almost exclusively to Gαi and regulates MAPK 
activity and cell growth while S1PR2 and S1PR3 have been shown to couple 
somewhat promiscuously to Gα12/13 and Gαq. Since both Gα12/13 and Gαq have been 
associated with RhoA activation (see [135] for review), we tested whether over 
Gα12/13 and the RGS-RhoGEFs stimulate SMC-specific transcription 
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expression of these G-proteins was sufficient to stimulate SMC-specific transcription. 
As shown in figure 2.2, over-expression of Gα12 (Q231L) or Gα13 (Q226L) in SMC 
activated SM22 and SM α-actin promoter activity approximately 2-3 fold while 
expression of Gαq (Q209L) had no effect. In contrast, over-expression of Gα12 
(Q231L) or Gα13 (Q226L) did not activate the c-fos promoter while Gαq (Q209L) did 
suggesting at least some specificity between the transcriptional responses to these 
G-protein sub-types. 
Previous studies have shown that RhoA activation by Gα12/13-coupled 
receptors is mediated by the Regulator of G-protein Signaling (RGS) sub-family of  
RhoGEFs that includes P115RhoGEF (P115), PDZ-RhoGEF (PRG), and Leukemia 
Associated Rho GEF (LARG) [135].  The RGS-RhoGEFs bind specifically to Gα12/13 
(through the RGS domain) and function as GAPs for these G-proteins. Importantly, 
this interaction also stimulates the GEF activity of RGS RhoGEFs providing a direct 
mechanistic link between Gα12/13-coupled receptors and RhoA activation. All three 
RGS-RhoGEFs are expressed in rat aortic SMC [86, 87] and interestingly, Becknell 
et. al. demonstrated that LARG expression in the lung and GI tract of the mouse was 
specific for the SMC layers in those organs [87]. Of additional importance to our 
studies, the RGS-RhoGEFs, unlike most other GEFs, specifically activate RhoA but 
not the closely-related small GTPases, Rac and Cdc42.  Based on these 
observations and our data implicating S1PR2 and Gα12/13 in the activation of SMC-
specific gene expression, we hypothesized that one or more of the RGS-RhoGEFs 
mediated the effects of S1P on RhoA in SMC and that this family of RhoA activators 
were important regulators of SMC phenotype. 
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Figure 2.2.  Gα12 and Gα13 increased SMC transcription. SMCs were co-
transfected with the indicated promoter-luciferase construct along with Gα12(Q231L), 
Gα13(Q226L), Gαq(Q209L), or empty expression vector (EV). Luciferase activity was 
measured 24h after transfection.  * p<0.05 vs EV. 
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To begin to examine the role of the RGS-RhoGEFs in SMC, we tested 
whether ectopic expression of these proteins in 10T1/2 cells could up-regulate SMC-
specific promoter activity. As shown in figure 2.3 over expression of LARG strongly 
increased (8-16 fold) the activities of the SM MHC, SM α-actin, and SM22 
promoters. The effects of PRG were somewhat less robust (~4-7 fold), but this 
difference may reflect slightly lower PRG expression levels in our experiments (see 
inset). Somewhat surprisingly, expression of P115 had only minor effects on SM 
MHC and SM22 promoter activity and no significant effect on SM α-actin promoter 
activity. Co-expression of C3 toxin, completely inhibited the transcriptional effects of 
all three RGS-RhoGEFs strongly supporting the involvement of RhoA in this 
response (data not shown). Since the effects of RhoA signaling on SMC-specific 
transcription are thought to be due to alterations in actin polymerization that regulate 
MRTF nuclear localization, we also tested the effects of the RGS-RhoGEFs on these 
parameters.  As shown in figure 2.3, over-expression of either LARG, PRG, or P115 
in 10T1/2 cells enhanced actin polymerization (Figure. 2.3b) and localization of GFP-
MRTF-A to the nucleus (Figure. 2.3c).  
To identify the RGS-RhoGEFs that were activated by S1P in SMC, we used 
an assay described by the Burridge lab that employs a nucleotide free variant of 
RhoA (G17A) to precipitate activated RhoGEFs from cell lysates [129]. As shown in 
figure 2.4a, treatment of SMC with S1P resulted in a dramatic increase in the 
amount of LARG present in GST-RhoA(G17A) precipitates suggesting that S1P  
The effects of S1P were mediated by LARG 
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Figure 2.3.  RGS-RhoGEF over-expression increased SMC transcription, stress 
fiber formation, and MRTF-A localization.  A.  10T1/2 cells were co-transfected 
with the indicated promoter-luciferase construct along with LARG, PRG, P115, or 
empty expression vector (EV). Luciferase activity was measured 24h after 
transfection.  * p<0.05 vs EV.  B.  10T1/2 cells expressing the indicated flag-tagged 
RGS-RhoGEF were stained with phalloidin to visualize actin polymerization.  C.  
10T1/2 cells were co-transfected with the indicated RGS-RhoGEF and GFP-MRTFA. 
Cell counts (>100 cells per condition) demonstrated that RGS-RhoGEF expression 
increased the percentage of cells that exhibited mainly nuclear MRTF-A localization 
(see lower right hand corner of micrographs in the middle column).  
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activates LARG in this model. LARG was also activated by 10% serum to a 
somewhat lesser extent. We observed little to no activation of PRG or P115 by S1P 
or serum. 
We next used a siRNA approach to test whether LARG was required for S1P-
mediated activation of RhoA in SMC. In parallel experiments we also knocked-down 
all three RGS-RhoGEFs in combination to examine potential compensatory effects 
within this family. We consistently achieved greater than 90% knock-down of LARG 
when compared to SMC transfected with a control siRNA that targets GFP, and we 
observed no up-regulation of either PRG or P115 in LARG knock-down cells (Figure 
2.4b). As measured by the Rhotekin-based assay (Cytoskeleton), knockdown of 
LARG in SMC inhibited S1P-dependent RhoA activation by approximately 65% 
(Figure 2.4c). In addition, depletion of LARG was as effective as the triple knock-
down providing further evidence that LARG is the major GEF within this family that 
mediates the activation of RhoA by S1P. LARG knockdown had no effect on S1P- or 
PDGF-bb mediated activation of MAPK (Figure 2.4d). 
Importantly, knockdown of LARG in SMC significantly inhibited S1P-
dependent activation of the SM22 and SM α-actin promoters (Figure 2.5a) and S1P-
dependent activation of endogenous SMC differentiation marker gene expression as 
measured by quantitative RT-PCR (Figure 2.5b).  Western blotting also 
demonstrated that LARG knockdown significantly inhibited S1P mediated increases 
in SM22, MHC, and SM α-actin protein levels by 45%, 52%, and 27%, respectively 
(see Figure 2.5c). In good agreement with the results from the RGS RhoGEF and 
RhoA 
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Figure 2.4. S1P induced RhoA activation in SMC was mediated by LARG.  A. 
SMCs were starved for 24 hours and then treated with S1P or 10% serum for 0, 3.5, 
or 9 min. Cell lysates were incubated with GST-Rho(G17A) coated beads and 
precipitates were analyzed for the presence of the indicated RGS-RhoGEF by 
Western Blot. The amount of RGS-RhoGEF protein present in cell lysates is 
presented at right.  B. Western Blot demonstrating significant knockdown of all three 
RGS-RhoGEFs using our siRNA transfection protocol. (NTC = Non-Targeted Control 
siRNA)  C. RhoA activation was measured in control, LARG, and triple knockdown 
cells using the G-LISA™ assay (Cytoskeleton) and is expressed relative to vehicle-
treated cells. At least 90% RGS-RhoGEF knockdown was ensured by Western Blot 
in all experiments (not shown).  * p< 0.05 vs S1P-treated NTC. D. Western blot of 
Control and LARG knockdown SMCs serum starved for 24 hours, treated for 12.5 
min, and probed for phosphorylated and total MAPK. 
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activity assays, single knockdowns of PRG or P115 had no effect on S1P-dependent 
SMC differentiation marker gene expression (data not shown). Taken together these 
results strongly indicate that S1P activates RhoA in SMC by activating LARG and 
that this signaling mechanism promotes SMC differentiation marker gene 
expression. 
Phenotypically modulated SMC exhibit increased migration, and it is well 
known that RhoA plays an important, yet complicated role in the regulation of this 
process. RhoA stimulates the formation of the stress fibers and focal adhesion 
complexes that promote firm cell adhesion. However, RhoA also regulates actin- 
myosin based contractility that is required for trailing edge retraction, and RhoA 
activity has been detected at the leading edge where it likely contributes to 
membrane protrusion by stimulating linear actin polymerization (see [136] for 
review). The mechanisms that regulate this shifting balance between cellular 
adhesion and cell movement are incompletely understood, and studies have shown 
that RhoA can inhibit or promote cell migration depending upon cell context [137-
139]. Given our demonstration that LARG promoted the differentiated SMC 
phenotype, we hypothesized that it may also inhibit SMC migration. To test this 
directly, we measured serum-induced migration in control and LARG knock-down 
SMC using a transwell assay. As shown in figure 2.6, migration was significantly 
increased in LARG knock-down SMC cells suggesting that LARG is a limiting factor 
in this assay.  We also assessed the effects of LARG on SMC migration in a scratch  
LARG inhibited SMC migration 
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Figure 2.5.  Knockdown of LARG inhibited S1P-induced up-regulation of SMC 
differentiation marker gene expression.  A. Control and LARG knockdown SMC 
were transfected with SM22 or SM α-actin specific promoter luciferase constructs 
and then serum-starved for 24 hours. Luciferase activity was measured after 8h of 
S1P treatment.  LARG knockdown was confirmed by Western Blot in all experiments 
(not shown). * p<0.05 vs. S1P-treated NTC.  B and C. Control and LARG 
knockdown SMC were serum-starved for 24 hours and then treated with S1P for an 
additional 24 h. Expression of the indicated SMC differentiation marker genes was 
measured by quantitative RT PCR (B)  and Western Blotting (C).  
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wound assay using live cell imaging. As shown in figure 2.6c, wound closure by 
SMC transfected with control siRNA was much slower than that in LARG knock-
down SMC which was virtually complete by 9h. Since wound closure can also be 
affected by changes in cell proliferation we used BrdU incorporation assays to 
determine cell proliferation indices in control and LARG knock-down SMC (see 
Figure 2.7).  As shown in figure 6b knock-down of LARG did not affect SMC 
proliferation strongly suggesting that the effects of LARG observed in the scratch 
wound model were due to decreased SMC migration.  
 
A growing body of evidence indicates that S1P regulates vascular function by 
controlling the growth, migration, contraction, and cell-cell interactions of endothelial 
cells and SMC (see [140] for review). The identification of the S1P-dependent 
signaling mechanisms involved has been complicated by the expression of multiple 
S1P receptors in the vessel wall and the promiscuous coupling of those receptors to 
G-proteins that have dramatically different effects on cell function. We were the first 
to demonstrate that S1P increased SMC differentiation in a RhoA dependent 
manner [120], and the current study supports previous studies implicating S1PR2 in 
this response [104, 113]. More importantly, we show that S1PR2-dependent 
activation of RhoA in SMC is mediated by LARG and that this RGS RhoGEF is a key 
component in the control of SMC phenotype. The identification of this signaling 
mechanism provides significant insight into the control of SMC function and into the 
vascular/SMC phenotypes observed in a variety of knockout models  
Discussion 
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Figure 2.6.  Knockdown of LARG increased SMC migration.  A.  Equal numbers 
of Control and LARG knockdown cells were plated on fibronectin coated transwell 
inserts and were allowed to migrate toward 10% serum-containing media for 18 h. 
Following fixation the number of cells that had migrated to the bottom chamber were 
visualized by crystal violet staining. SMC migration was evaluated in 3 separate 
experiments and is expressed relative to migration of control cells set to 1.  * p<0.05 
versus control.  B.  Control and LARG knockdown SMC were treated with BrdU for 
18 h prior to fixation. The percentage of BrdU-containing nuclei in each group was 
determined by immunohistochemistry.  C. Confluent cultures of Control and LARG 
knockdown SMC were scraped with a P200 tip and then placed on an inverted 
microscope equipped with a heated, humidified, and O2/CO2 perfused stage. 
Pictures taken every 3.5 minutes for 9 h were assembled into movies using 
Quicktime (0h and 9h frames shown). 
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Figure 2.7.  LARG over-expression has no effect on IL-2 promoter activity.  A.  
SMCs were transfected with control and IL-2 luciferase fused promoter construct.  
After 24 hours cells were starved for 8 hours and treated with vehicle or Ionomycin 
[5µm]. Luciferase activity was measured 8 hours after treatment (N=3). B.  SMCs 
were co-transfected with control and IL-2 luciferase fused promoter construct and 
empty expression vector or LARG. Luciferase activity was measured 24h after 
transfection (N=3).  
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The analysis of S1P receptor sub-type-specific knockout mouse models has 
yielded important information on the role of S1P receptor signaling in the 
vasculature.  S1PR1-deficient mice die around E13.5 and have a defect in SMC 
investment of the dorsal aorta [94]. However, because a similar phenotype was 
observed in EC-specific S1PR1 knockouts [141], this effect was likely secondary to 
defects in EC tube maturation and not to defects in SMC differentiation per se. 
Vascular abnormalities were not observed in S1PR2 deficient mice [100], but the 
earlier lethality and increased hemorrhage observed in S1PR1/S1PR2 and 
S1PR2/S1PR3 double knockouts [142] suggests that S1PR2 may have an 
independent role in the establishment and maintenance of a mature vasculature. 
Although it has been difficult to determine whether SMC differentiation during 
development was affected by the loss of S1PR2, Shimizu et. al. have directly 
implicated S1PR2 in the regulation of SMC phenotype in adult animals [103]. Using 
a carotid artery ligation model these authors demonstrated that S1PR2 deficient 
mice had larger neointimas [103] and reduced SM α-actin expression following 
vessel injury [104].  
Our results also implicate Gα12/13 in the regulation of SMC differentiation. 
When coupled with the branchial arch SMC defect observed in MRTF-B deficient 
mice [46, 47], it is intriguing to postulate that G12/13 signaling to RhoA plays a critical 
role in the differentiation of cardiac neural crest cells into SMC. Interestingly, neural 
crest cell-specific deletion of Gα12/13 signaling resulted in proximal outflow tract 
defects and the development of an aneurysm-like structure in the septal branch of 
the left coronary artery [143]. Because cell tracing analyses demonstrated that 
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neural crest cell migration to these structures was not impaired, these phenotypes 
may have resulted from defects in the differentiation/maturation of these cells into 
SMC. In addition, deletion of endothelin receptor A, another Gα12/13-coupled receptor 
that activates SMC contraction and SMC differentiation marker gene expression 
[144, 145], also resulted in defective outflow tract development [146].  
Our demonstration that S1PR2 signals through LARG may have important 
implications on the control of vascular tone. Extensive evidence indicates that RhoA 
regulates SMC contraction by inhibiting myosin phosphatase (see [147] for review), 
and several in vitro studies have shown that S1P constricts vessels by a RhoA 
dependent mechanism [148, 149]. Adult S1PR2 deficient mice have relatively 
normal systemic blood pressure, but flow measurements showed decreased 
resistance in mesenteric and renal vascular beds especially in the presence of 
adrenergic stimulation [150]. It has also been postulated that the deafness observed 
in S1PR2 deficient mice may be due to dilation of the spiral modiolar artery that 
supplies blood to the inner ear [102]. LARG knock-out mice also have relatively 
normal blood pressure, but were shown to be less susceptible to salt-sensitive 
hypertension [89]. Thus, we feel that S1PR2-dependent activation of LARG could 
serve a critical role in blood pressure regulation and that targeting this pathway 
could be beneficial in the treatment of hypertension. S1P also affects vascular tone 
by increasing in intracellular calcium, an effect most likely mediated by S1PR3 [100]. 
Interestingly, recent studies have demonstrated that calcium may also be important 
for SMC differentiation marker gene expression and that cross-talk between calcium 
and RhoA may be involved [113, 126].  In our model over-expression of LARG in 
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SMC did not activate the calcium/calcineurin-dependent IL-2 promoter suggesting 
that LARG does not significantly activate calcium signaling (see Figure 2.7). 
However, it is possible that these two pathways act in parallel to regulate SMC-
specific transcription or that they intersect further downstream. 
The residual S1P-dependent RhoA activity observed in LARG deficient SMC 
could be due to incomplete knockdown of LARG expression but could also reflect 
the contributions of S1PR3 coupling to Gαq. Gαq has been shown to activate RhoA 
and SRF-dependent transcription through a separate family of RhoGEFs that 
includes Trio, Duet, and p63RhoGEF [151]. In support of this idea, Ishii et al. 
detected residual S1P-dependent RhoA activity in S1PR2 deficient fibroblasts but no 
S1P-dependent RhoA activity in fibroblasts isolated from S1PR2/S1PR3 double 
knockouts [100]. The increased lethality and hemorrhage observed in the 
S1PR2/S1PR3 double knockout mice also supports this concept [142]. Surprisingly, 
Gq did not stimulate SMC-specific transcription in SMCs, but it is possible that these 
RhoGEFs are not highly expressed in these cells. Compensatory RhoA activation 
may also explain the lack of a significant SMC phenotype in S1PR2 and LARG 
knockout mice during development and why SMC phenotypes have been revealed 
only under conditions of vascular stress (i.e. artery ligation or salt-induced 
hypertension).  
Although all three RGS-RhoGEFs are expressed in SMC and are sufficient to 
increase actin polymerization and EGFP-MRTF-A localization when over-expressed 
in 10T1/2 cells, we detected little to no RGS-RhoGEF activity in serum-starved SMC, 
and only LARG was activated by S1P. The latter result supports previous studies 
54 
 
demonstrating that specific Gα12/13-coupled agonists activate specific RGS-
RhoGEFs. For example, activation of RhoA by thrombin in PC-3 prostate cancer 
cells was primarily mediated by LARG [152] while activation of RhoA by 
lysophosphatidic acid in HEK293 cells was mediated by PRG [153]. Although the 
molecular interactions within the agonist-receptor-Gα12/13 complex that mediate this 
specificity are currently unknown, agonist-specific RGS-RhoGEF activation could 
provide an additional level of control over RhoA activity and could help integrate 
multiple RhoA-dependent signals. Further supporting differential activation of the 
RGS-RhoGEFs, Guilluy et. al. recently demonstrated in SMC (using the G17ARhoA 
pull down assay) that angiotensin II treatment specifically activated P115 [154]. 
These authors also described a novel mechanism of P115 activation that was 
mediated by JAK2-dependent tyrosine phosphorylation. In our experiments P115 did 
not activate SMC-specific promoter activity as strongly as LARG or PRG but did 
result in increased actin polymerization and MRTF-A nuclear localization. These 
data suggest that additional signals might be required to fully activate MRTF-A 
dependent transcription or that the RGS-RhoGEFs might act on separate pools of 
RhoA that differentially affect MRTF-A activity. Interestingly, qualitative assessment 
of P115-expressing cells revealed a more cortical pattern of actin polymerization. 
P115 lacks the PDZ domain present in LARG and PRG, but whether this difference 
significantly affects P115 activation, function, and/or localization has not been 
directly tested in our model. 
Our demonstration that LARG decreases SMC migration provides 
mechanistic insight into the control of cell migration by RhoA and helps explain the 
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anti-migratory effects of S1PR2-dependent signaling observed in several of other 
models [155, 156]. Importantly, our results are in excellent agreement with the 
previous demonstration that S1PR2 deficient SMC exhibit increased migration [103], 
and strongly suggest that this effect is due, at least in part, to decreased LARG 
activity. Ong et al. have recently shown that expression of LARG in breast and 
colorectal cancer cells markedly inhibited migration [157] providing further evidence 
that LARG inhibits this process. The precise mechanisms for the anti-migratory 
effects of LARG are not completely understood but may involve increased cell 
adhesion. For example, Dubash et.al. have shown that siRNA depletion of LARG 
decreases stress fiber and focal adhesion formation [158].  Clearly, additional 
studies will be necessary to identify the spatial and temporal patterns of RhoA 
activation that are necessary for cell migration and to determine whether LARG (and 
other RhoGEFs) activate RhoA within specific cellular compartments.
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 Actin based cytoskeletal rearrangements regulate a multitude of cellular 
physiological responses and signaling events.  Dorsal ruffles establish polarity and 
initiate migration transitioning cells from a static to motile state.  Despite the 
importance of these events the molecular regulation of these structures has 
remained elusive.  While studying the RhoA mediated transcriptional response of 
SMCs we serendipitously discovered the presence of two RGS RhoGEFs, LARG, 
and P115, in dorsal ruffles. We used immunofluorescence and Laser scanning 
confocal microscopy to confirm co-localization of multiple dorsal ruffle markers with 
LARG and P115 in PDGF-bb-induced SMC dorsal ruffles.  Endogenous depletion by 
siRNA mediated knockdown revealed a differential effect on the rate of dorsal ruffle 
formation.  In comparison to control knockdown cells LARG depletion inhibited 
dorsal ruffle formation while P115 depletion increased the occurrence of dorsal 
ruffles.   
Abstract 
Since dorsal ruffles are known to regulate motility we studied the contribution 
of LARG and P115 to the regulation of directional migration as well as wound 
healing.  Again we observed differential effects compared to control cells with LARG 
depletion increasing migration and P115 depletion inhibiting migration possibly due 
to polarity defects.  We hypothesize that the difference in signaling is a result of 
preferential interaction of downstream signaling proteins with one of these GEFS.  
The mDia formin is a well known actin regulator and RhoA effector.  We show that 
LARG interacts with mDia in SMC and that both mDia 1 and 2 localize to dorsal 
ruffles.  Understanding the molecular regulation of dorsal ruffles will provide insight 
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to the establishment of polarity and initiation of migration in SMC and by extension 
the processes that govern vascular development and the pathogenesis of CVD.  
Actin based structures regulate cell shape, adhesion, contractility, 
proliferation, and motility. Understanding the physiologic role, structure, and 
molecular composition of these structures is the key to understanding the 
mechanisms that drive their functional specificity.  Traditionally our understanding of 
these actin based structures has been that stress fibers regulate cell contractility, 
filopodia direct growth and initiate adhesion, and lamellipodia form the leading edge.  
Furthermore it has been understood that RhoA, cdc42, and Rac1 regulate these 
processes respectively.  Dorsal ruffles represent a fourth, unique, cytoskeletal 
structure whose impact on cell behavior is equally profound, but in comparison to 
other actin based structures the regulation of dorsal ruffles is poorly understood.  
What is now becoming evident is that the small GTPases of the Rho family often act 
in concert, with a balance of additive and opposing effects on one another, and that 
regulation of cytoskeletal events ultimately depends upon the spatiotemporal 
juxtaposition of Rho family GTPase activity and a host of interacting and scaffolding 
proteins. 
Introduction 
Stress fibers, lamellipodia, filopodia, and dorsal ruffles are all actin based 
structures that carry out different roles in cellular physiology.  The Rho family of 
small GTPases are well known regulators of these structures.  Stress fibers are 
regulated by the small GTPase RhoA. The physiological role of stress fibers is to 
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anchor within cells and regulate cell adhesion by allowing myosin motors to generate 
force during contraction.  This force can be used to power migration or to conduct 
mechanotransduction [159].   Stress fibers are higher order structures composed of 
polymerized and bundled actin filaments, crosslinking proteins i.e. filamin, α-actinin, 
and myosin II motors.   
Lamellipodia formation is regulated by Rac1 signaling.  However, in these 
structures the actin takes the form of multi nucleated webs or networks constantly 
turning over driving a wide meshwork outward in a thin membrane bound sheet of 
cytoplasm.  Globular actin is quickly converted into thinner polymerized actin 
filaments that are often nucleated to create multiple branch points generating an 
expanding network.  As quickly as nucleation drives branched actin polymerization, 
other proteins regulate the disassembly at the rear of these actin structures 
increasing actin turnover providing additional g-actin to drive meshwork expansion.  
The Arp2/3 complex and associated scaffolding proteins like WAVE and WASP drive 
leading edge protrusion while capping proteins as well as gelsolin or ADF/cofilin are 
also important in the posterior disassembly of actin filaments [160, 161].   
Filopodia formation is driven by the small GTPase cdc42.  These structures 
function as sensory organelles or as a precursor of adhesion sites and stress fiber 
formation [162-165].  Filopodia, also known as microspikes, play an important role in 
neurite outgrowth, wound healing, and cell migration.  Structurally, filopodia take the 
shape of actin filled membrane projections of around 100-300nm in diameter.  
Filopodia are composed of polymerized actin strands and crosslinking proteins like 
fimbrin. Other proteins found in filopodia promote un-branched elongation.  
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ENA/VASPs for instance have anti capping activity while formins like Dia1/2 
increase processive barbed-end nucleation and elongation [166-168]. 
A major goal of this work was to characterize sub cellular activation of RhoA 
in SMC.  As a first step we used immunoflourescence to determine the effects of 
agonist stimulation on Leukemia Associated Rho GEF (LARG) localization.  Serum 
treatment at the shortest time points revealed localization of LARG at circular 
structures forming on the cells.  Realizing that the structures resembled dorsal 
ruffles, time courses were shortened to the 5-20 minute range, PDGF-bb was used 
as an agonist, and a number of other proteins known to localize to dorsal ruffles 
were probed for, concurrent with LARG and P115.   
The function of dorsal ruffles is not completely clear.  The term dorsal ruffle 
was first used in 1983 to describe the dynamic actin based structures that occurred 
in glial cells as a response to PDGF-bb treatment [169].  Since then these structures 
have been observed in a number of cell types including fibroblasts, endothelial cells, 
hippocampal neurons, lymphocytes, tumor cells, and vascular smooth muscle cells, 
indicating structural relevance in a number of physiological contexts [169-175].  
Visually the protrusion of a dorsal ruffle is reminiscent of the linear, unbranched, 
bundled formations that compose filopodia or even stress fibers. Dorsal ruffles form 
on the dorsal surface of a cell extending upward and are likely to function in the 
degradation of stress fibers both establishing polarity and initiating conversion of 
cells from a static to motile state. The upward push and eventual internalization of 
dorsal ruffles results in detachment of adhesions to the extracellular matrix.  
Moreover stress fiber disassembly provides a surplus of unbundled cortical actin 
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useful in lamellipod extension [172, 176].  When this surplus of G-actin is localized to 
one side of the cell, polarity is established and lamellipodia formation is directed at 
the dorsal ruffle forming edge of the cell [177, 178].  The evidence of dorsal ruffle 
induced polarity was best described by McNiven et al. who show with time lapse 
photography that as dorsal ruffles constrict to a reduced diameter there is a 
concomitant protrusion at the cell periphery where the ruffle disappeared that 
becomes smooth and polarized forming a single large lamellipodia [172].   
Additionally receptor internalization, plasma membrane recycling, and 
macropinocytosis have been proposed as secondary functions to occur during 
dorsal ruffle resolution[171, 179-182].   Despite their appearance the composition of 
dorsal ruffles is similar to that of lamellipodia as both of these structures include 
Arp2/3, Wave/WASP, and gelsolin.  The components are not identical however as 
Rab5 as well as Rac1 has been shown to regulate dorsal ruffle formation [183]. Two 
interesting proteins unique to dorsal ruffles are the large G proteins Gα12 and Gα 13.  
It has been shown that Gα12 and Gα13 both co-localize to dorsal ruffles.  These 
authors show that fibroblast cells that are deficient in Gα12 and/or Gα 13 show similar 
ability to form dorsal ruffles upon PDGF treatment but that the dorsal ruffles in the 
Gα12/13 null cells took much longer to disassemble. The authors conclude that Gα12/13 
accelerate dorsal ruffle turnover.  The proposed mechanism the authors put forth, 
based on Rac1 FRET analysis in these Gα12/13 null cells, is that the G proteins 
control dorsal ruffle disassembly by shortening the duration of Rac1 signaling,  
though they stop short of explaining how [184].   
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Dorsal ruffles differ from other actin based cytoskeletal structures in a few 
ways.  Unlike lamellipodia or membrane waves which are very transient and reform 
quickly, a dorsal ruffle will form only once.  Unlike podosomes or invadosomes (other 
circular actin based cytoskeletal rearrangements) which are MMP rich and function 
to anchor or invade a matrix, dorsal ruffles form on the dorsal surface of a cell 
extending upward and do not assist in invasion or anchorage.  Dorsal ruffles are the 
earliest cytoskeletal rearrangements to occur in a cell and assemble within minutes 
upon agonist stimulation with dorsal ruffles lasting for 5 to 20 minutes [185]. Dorsal 
ruffles form in response to a number of receptor-tyrosine-kinase growth factors, most 
notably in response to platelet-derived growth factor (PDGF) but also form in 
response to TPA and neomycin [170, 186].   
Though dorsal ruffles are purportedly mediated in a Rac1 dependent manner, 
multiple Rho family GTPases have been observed in dorsal ruffles including Rab5, 
Rac, Ras, and Arf6 [183, 187]. In fact, Wang et al. showed that although dominant 
negative Rac expression blocked PDGF-induced dorsal ruffling, constitutively active 
Rac1 over expression was incapable of inducing dorsal ruffles.  This indicates that 
though Rac is required for dorsal ruffles it, alone, is not sufficient.  Multiple Rho 
GTPase regulatory proteins have also been observed in dorsal ruffles.  ACAP1/2 as 
well as ASAP1, each GAPs for ARf6 have been observed in circular dorsal ruffles 
(CDR) [187, 188]. Two Rac specific GEFs Swap70 and β-PIX have been observed 
in dorsal ruffles and are believed to positively regulate their formation [189, 190]. 
Our demonstration of LARG and P115 in dorsal ruffles suggests that the 
spatiotemporal regulation of RhoA can further explain the complicated role that the 
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GTPase plays in the regulation of cell migration. RhoA was originally shown to be 
responsible for the formation of the stress fibers and focal adhesion complexes that 
regulate cell shape and adhesion [191]. However, RhoA and the RhoA effectors 
such as the Diaphanous proteins can mediate actin polymerization that drives cell 
extension at the leading edge.  RhoA activity is also required for retraction of the 
trailing edge of cells during directional movement because it regulates actin-myosin 
based contractility [192]. The mechanisms that regulate this shifting balance 
between cellular adhesion and cell movement are not well known understood but 
probably involve localized activation of each of the small GTPases. Interestingly, 
some studies have shown that expression of a dominant negative RhoA attenuated 
membrane ruffling and lamellipodia formation, focal complexes/adhesion turn-over, 
and cell migration [139], while others have shown that RhoA activity correlates with 
the strength of cell adhesion to the ECM and that decreased Rho activity is 
permissive for increased migration [138]. Clearly it will be critical to identify the 
mechanisms that regulate RhoA's many different functions during the process of 
migration. 
In addition to the spatiotemporal regulation of RhoA there is increasing 
evidence that significant cross talk exists between many of the Rho family GTPases 
and that Rac1 and RhoA specifically have extensive regulatory effects on one 
another [193-198].  Indeed in other Rac mediated cytoskeletal rearrangements RhoA 
has been shown to play an important role, Cascone et al. have shown that Tie-2 (a 
tyrosine kinase receptor)-mediated shape change requires cooperative activation of 
both RhoA and Rac1[199].  Also Sepp et al. have shown that both RhoA and Rac1 
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have distinct but interdependent roles in glial cell migration and nerve ensheathment 
[200].  These examples of RhoA/Rac1 cross talk have been proven relevant in the 
regulation of actin based cytoskeletal structures but the mechanisms that govern 
their antagonism have not been investigated. 
The goal of this study is to understand the role that the RGS RhoGEFs play in 
the regulation of dorsal ruffle formation as well as migration and to determine the 
mechanism or proteins involved in differentially regulating LARG and P115 
associated dorsal ruffles. We hypothesize that spatiotemporal regulation of RhoA 
activation, possibly through a Rac1 antagonism mechanism elicits the increase in 
dorsal ruffle formation observed in P115 KD cells and that LARG mediated actin 
polymerization localized by interaction with mDia1/2 explains the decrease in dorsal 
ruffle formation observed in LARG KD cells. 
Plasmids and Reagents- LARG, PRG, and P115 cDNAs were kind gifts from Dr. T. 
Kozasa (University of Tokyo). All cDNAs were sub-cloned into pcDNA 3.1. 
Antibodies to LARG and PRG were kind gifts of Dr. Keith Burridge (University of 
North Carolina, Chapel Hill, NC). Primary antibodies for endogenous detection 
include P115RhoGEF (SantaCruz sc-20804), vinculin  (Sigma V4505), cortactin 
(Millipore 4F11), mDia1(Santa Cruz sc-10886), and mDia2 (Santa Cruz sc-10894).    
Alexa Fluor 555 or 488 (Molecular Probes) secondary antibodies and DAPI 
(Molecular Probes) were used at 1:2000 and 1nM, respectively. 
Materials and Methods 
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Cell Culture, Transfections, and Reporter Assays- The 10T1/2 and SMC cell 
cultures, transient transfections, and promoter luciferase assays have been 
previously described [44, 120].  
Immunofluorescence - SMCs were plated and transfected in 2 or 4-well chamber 
slides, maintained in 10% serum overnight. Cells were serum-starved for at least 16 
hours and treated with PDGF-bb for 7 or 15 min, fixed in 3.7% 
paraformaldehyde/PBS for 20 min and permeabilized in 0.5% Triton X-100/PBS for 
3-4 min. Transfected cells were incubated with M2 anti-flag (1:500)(Sigma) or LARG 
or P115 antibodies in 20% Goat Serum / 3% BSA in PBS for 2 hours 
Immunoprecipitation- Cultured SMC lysates were purified and pre-cleared with PAS 
beads.  1.2mg of lysates were then incubated with 10ul of anti-LARG for 2 hours.  
PAS beads were added to mix for 2 hours prior to washes and westerns were 
performed.  
siRNA knockdowns - All siRNA oligos were designed using Invitogen algorithms, 
and purchased from, Invitrogen.  Transfection of 21NT siRNA oligos was 
accomplished with Dharmafect transfection reagent as per protocol. A cocktail of two 
separate siRNA oligos was used for each GEF. 
siRNA KD-  RGS RhoGEF KD Sequences 5’3’ 
LARG1-AAACCAAAUGUAUAGAGCUTT 
LARG2-CCCACUUGCUGAUUCUGAATT  
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P1151-AUCUUCUGAGUUCGCCUCCTT  
P1152-UUAGAUGUCGACAAUCUGGTT 
Transwell Assays- In brief SMCs were transfected with control LARG pr P115 
specific siRNA.  After 72 hours of KD cells were split, counted, and equalized. Three 
thousand cells were plated on the tops of fibronectin coated transwells (8µm pore 
size) in a 24 well format.  Cells were allowed to migrate toward DMEM F-12 + 10% 
serum in the bottom chamber for 18 hours prior to processing. Chambers were 
rinsed with PBS, cells were removed from the top chamber by scraping with a cotton 
swab, and the remaining cells (in the bottom chamber) were fixed in 4% 
paraformaldehyde for 20 min. Cells that had migrated to the bottom chamber were 
visualized by crystal violet staining for 4 hours. Data represent the total number of 
cells in 12 separate fields for each condition through three separate experiments. 
Migration Assays - For wound healing assays, confluent cultures of control and 
LARG knockdown SMC were scraped with a P200 tip and then placed on an 
inverted microscope equipped with a heated, humidified, and O2/CO2 perfused 
stage. Pictures taken every 3.5 minutes for 15 hours were assembled into movies 
using Quicktime.  Individual frames were isolated from quicktime movies and 
analyzed by image J software to calculate the wound area at time=0 and time= 
15hours.  The area at 15 hours was divided by the initial wound area.  That 
percentage was subtracted from 1 to determine the percent wound closure.   At the 
end of each experiment cell lysates were subjected to western blot to ensure LARG 
knockdown.  
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Wound Healing Assay Equipment Specifics-   Equipment and instruction was 
provided by Dr. C. Robert Bagnell, Jr., Ph.D. Professor and Director of the 
Microscopy Services Laboratory at UNC Chapel Hill.   
Olympus IX70 Live Cell Inverted Fluorescence Microscope Description:  The 
Olympus IX70 is an inverted microscope equipped for bright field, phase contrast, 
and epifluorescence. It is enclosed within an environmental chamber capable of 
controlling both temperature and relative humidity. It is equipped with a Uniblitz 
shutter on the transmitted light system and a Ludl stepper moror filter/shutter 
controller on the epifluorescence system, a BioPrecision motorized stage with linear 
encoders and motorized focus with servo feedback all controlled by a LEP MAC5000 
controller. Image capture is by a Hamatsu ORCA CCD camera. The system is 
controlled by an Apple IMAC computer using Improvision’s Open Lab software. 
Carbon dioxide supply is provided from a 100% CO2 tank connected to a flow meter 
and controlled by a precision needle valve. CO2 is passed through a water column 
and delivered through tubing to custom-made tabulated lids that match various cell 
culture dish configurations. 
Confocal Laser Scanning Microscopy-  Cell preparation and Immunofluorescence 
procedures were identical to those previously outlined.  A Carl Zeiss Pascal Laser 
scanning confocal scope was used to obtain images resolved to 0.46µm in the z-
axis.  Scanning was delayed between 488 (FITC) and 555(Rhodamine) channels to 
ensure no residual signal between scans.  Zeiss LSM Image browser version 
4.2.0.121 was used to process images generated and conduct overlay analysis.  
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Results 
RGS RhoGEF localization is likely important in regulating RhoA mediated 
cytoskeletal structures. To comprehensively examine the endogenous localization of 
these GEFS we needed to optimize our immunoflourescence procedures for 
compatibility with endogenous GEF antibodies.  The LARG and P115 antibodies 
used in these studies have not been thoroughly tested for use in 
immunofluorescence based applications.  We first tested the specificity of these 
antibodies in our immunofluorescence protocols.  In figure 3.1a, we transfected 
10T½ cells with flag-tagged plasmids for LARG and P115, and then probed with an 
anti-flag antibody and antibodies specific to LARG and P115.  As you can see cells 
that express a flag tag have a highly elevated expression level of either LARG or 
P115 indicating specificity for the endogenous antibodies. 
Development of IF Methods for endogenous RGS RhoGEF Localization 
In our initial examination we observed occasional RGS RhoGEF localization 
to circular structures after 15-20 minutes of serum stimulation.  To test whether 
these structures were dorsal ruffles we grew primary smooth muscle cells to 
approximately 70% confluence, and treated the cells with PDGF-bb, a known 
inducer of dorsal ruffles. Cells were fixed and stained or probed for known 
components of dorsal ruffles including polymerized actin (via phalloidin), cortactin, 
and vinculin along with LARG or P115 [170, 172, 187, 201]. Using confocal laser 
scanning microscopy we show that both LARG and P115 co-localize phalloidin, 
LARG and P115 localize to dorsal ruffles 
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cortactin, and vinculin upon PDGF-bb induced dorsal ruffle formation (Figure 3.1b 
and c). 
After discovering the presence of these GEFs in dorsal ruffles we wanted to 
test whether these GEFs play a role in the regulation of their formation.  Gα12 and 
Gα13 have been shown to interact with these GEFs and to localize to dorsal ruffles.  
Functional analysis of dorsal ruffle duration in Gα12 and Gα13 null fibroblasts 
revealed that the duration of dorsal ruffles was increased indicating Gα12 and Gα13, 
when active, increase dorsal ruffle disassembly.  The RGS domains of LARG and 
P115 are known to increase GTP hydrolysis of Gα12/13 subunits inhibiting their 
signals to downstream effectors.  Based on these data we hypothesized that 
depletion of the GEFs LARG and P115 would increase the ratios of GTP or activated 
Gα12 Gα13 increasing dorsal ruffle turnover. To investigate this possibility we 
depleted LARG and P115 in smooth muscle cells by transient transfection of 
siRNAs.  After siRNA mediated depletion we starved primary smooth muscle cells, 
treated with PDGF-bb, and scored the number of dorsal ruffles in non-target control, 
LARG KD, and P115 KD SMCs.  Our initial hypothesis was supported by the 
observation that the number of dorsal ruffles was reduced in the LARG KD cells but 
we were surprised to observe that P115 depletion increased the incidence of dorsal 
ruffle formation (Figure 3.2). 
LARG and P115 depletion differentially effect dorsal ruffle formation  
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Figure 3.1. LARG and P115 localize to dorsal ruffles. A. SMCs were transfected 
with flag tagged versions of LARG and P115.  Cells were probed with flag and LARG 
or P115 antibodies and visualized with Alexa Fluor conjugated secondary 
antibodies. B.  Smooth muscle cells were grown to near confluence, starved over 
night, stimulated with PDGF-bb for 7 minutes and probed for LARG and indicated 
dorsal ruffle associated proteins.  Confocal images are depicted. C. Cells were 
processed identically to those in 3.1b but probed for P115 instead. 
C. 
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Figure 3.2. LARG and P115 knock down differentially effect dorsal ruffle 
formation. A.  LARG, P115, and control siRNA oligos were transfected in SMCs 
plated on chamber slides.  After 3 days cells were starved and treated with PDGF-bb 
for 7 minutes.  Cells were fixed and stained for phalloidin.  Dorsal ruffle formation 
was normalized to control cells.  Fields were chosen by dapi stain and counts were 
done independently among different experiments to avoid bias. *P<0.05 
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Two of the physiological functions of dorsal ruffles are the establishment of 
polarity and the initiation of migration.  We have previously shown that LARG 
depletion increases SMC migration indicating that LARG negatively regulates this 
process [202]. Conversely, P115 KO studies in neutrophils concluded that P115 is 
required for normal polarization and directional migration.  To test whether depletion 
of LARG and P115 would differentially effect SMC migration we transfected siRNA 
oligos into primary SMC and measured directional migration and wound healing.   
LARG and P115 differentially regulate SMC migration 
Directional migration measured by transwell assay, as shown in figure 3.3a, 
reveals that depletion of LARG causes a nearly 150% increase in migration whereas 
depletion of P115 results in an equally dramatic decrease in migration.  These 
changes are mirrored in wound healing assays as well.  Scratch wounds are induced 
in monolayers of control or GEF depleted SMCs and live cell imaging was done to 
construct time lapse movies of migration.  Figure 3.3b shows frames taken at time 0 
and after 15 hours of migration.  Cell transfected with a non-target control show an 
intermediate capacity for wound closure compared to LARG KD which healed more 
quickly and P115 KD cells which healed comparatively slowly.  Quantification of the 
initial wound area compared to the remaining wound area after 15 hours is shown in 
figure 3.3b.  
The RhoA effectors mDia 1 and 2 are members of the subfamily of 
diaphanous-related formins (DRFs)which are identified by conserved formin  
LARG and mDia 1 and 2 bind and co-localize to dorsal ruffles 
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Figure 3.3. LARG and P115 Differentially Regulate SMC migration. A.  Equal 
numbers of control, LARG, and P115 knockdown cells were plated on fibronectin-
coated transwell inserts and were allowed to migrate toward 10% serum-containing 
media for 18 hours.  Following fixation, the number of cells that had migrated to the 
bottom of the chamber were visualized by crystal violet staining.  SMC migration was 
evaluated in three separate experiments is expressed relative to migration of control 
cells set to 1. *P<0.05 B. Confluent cultures of control, P115, and LARG knockdown 
SMC were scraped with a P200 tip and then placed on an inverted microscope 
equipped with a heated, humidified, and O2/CO2 perfused stage. Pictures taken 
every 3.5 minutes for 15hours were assembled into quicktime movies. (0 and 15 
hour frames shown) Image j was used to quantify wound area in control, P115, and 
LARG knockdown SMCs before and after 15 hours of migration.  Final area was 
divided by initial area and that ratio was subtracted from 1 to determine percent 
wound closure as indicated in the lower right corner of 15hr panels. 
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homology (FH) domains, a conserved GTPase binding domain (GBD) that interacts 
with Rho family GTPases, and a Diaphanous Auto-regulatory Domain (DAD).  It has 
been well defined that binding of the GBD by RhoA activates Dia in SMC promoting 
actin polymerization [203].  mDia mediated actin polymerization is an important step 
in cytoskeletal regulation.  For instance, mDia has been shown to increase 
processive barbed-end nucleation and elongation in filopodia formation.  
There are four published papers that suggest a LARG/Dia interaction.  One 
study that highlights Dia LARG interaction shows that the Drosophila LARG homolog 
dRhoGEF2 co-localizes with Dia at the furrow canal during cellularization [204]. A 
second study suggests a role for LARG and Dia upstream of RhoA.  These authors 
use LPA, an agonist that stimulates Gα12/13 coupled receptors to show that Dia can 
stimulate LARG mediated activation of RhoA creating a positive feedback loop [203].  
These authors show that Dia1 binds LARG and determine the general region in 
which these proteins bind but stop short of determining the exact residues.  Another 
study conducted in neutrophils showed that LARG and mDia1 co-localize at the 
leading edge during migration and that Dia facilitates the recruitment.  They also 
show that this interaction is important upstream of RhoA by showing that in Dia -/- 
cells LARG is less efficient at activating RhoA [205]. In the fourth study, Gourlimari 
et al suggest LARG and mDia1 link Gα12/13 to cell polarity and microtubule dynamics 
[206]. All of these studies link Dia and LARG to either RhoA activation or actin 
dynamics or both but they are all limited to mDia1 and none of the studies were 
conducted in smooth muscle. 
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Previously we have shown that SMC specific transcription and RhoA activity 
is preferentially activated by LARG in SMC when compared to P115 but the 
mechanisms governing this difference were not explored.  It is possible that the 
difference in dorsal ruffle regulation observed by LARG and P115 depletion is the 
result of a divergence in their individual binding partners and downstream signaling 
pathways.  Given the possibility that these differences are achieved by RhoA 
effectors that regulate actin dynamic we chose to look at the mDia formins and their 
interaction with LARG. 
To determine co-localization of mDia1 and 2 with LARG in dorsal ruffles we 
serum starved primary aortic SMCs, treated with PDGF-bb, and probed with LARG 
and mDia1 and 2 specific antibodies.  In figure 3.4a we show that both mDia1 and 
mDia2 co-localize with LARG to dorsal ruffles.  The association of LARG and mDia1 
is well documented but to confirm the interaction of LARG and mDia2 we performed 
co-immunoprecipitations with anti-LARG and probed for mDia2.  In figure 3.4b we 
show by IP with anti-LARG that LARG associates with mDia2. 
We have shown that the RhoA-specific GEFs LARG and P115, localize to 
dorsal ruffles upon PDGF stimulation. Depletion studies of LARG and P115 both had 
an effect on dorsal ruffle formation.  The loss of LARG in SMC showed impaired 
ability to form dorsal ruffles whereas depletion of P115 resulted in an increased rate 
of dorsal ruffle formation.  Transwell and wound healing assays of LARG and P115 
KD SMCs also revealed differential effects.  When compared to control cells LARG  
Discussion 
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Figure 3.4. LARG and mDia 1 and 2 bind and co-localize to dorsal ruffles. A.  
FFSMC lysates were purified and incubated with LARG antibody and anti-rabbit 
conjugated PAS beads or just anti-rabbit conjugated PAS beads. Westerns were run 
and probed for Dia2 and LARG. B. Smooth muscle cells were grown to near 
confluence, starved over night, stimulated with PDGF-bb for 7 minutes and probed 
for LARG and mDia1 or 2. Confocal images are depicted. 
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depleted cells showed increased directional migration and wound closure, whereas 
P115 depleted cells showed reduced directional migration and wound healing.  
Furthermore we show that the actin polymerizing formin Dia binds to LARG and co-
localizes to dorsal ruffles.   
While identified and coined in 1983 dorsal ruffles have enjoyed relatively little 
scrutiny in comparison to their structural cousins stress fibers, lamellipodia, and 
filopodia.  Despite their understudied status, dorsal ruffles, with their ability to 
establish polarity and initiate migration, are structures of significant physiological 
relevance [172, 176-178].  In this study we discovered two RhoA regulating proteins 
of the RGS RhoGEF family in circular dorsal ruffles.  Interestingly LARG and P115 
had differential effects on dorsal ruffle formation. To our knowledge this is the first 
report to implicate RhoA in the regulation of these structures. 
Somewhat surprisingly we discovered that these highly similar proteins 
differentially regulate dorsal ruffle formation, a finding that mirrored LARG and 
P115’s ability to inhibit and promote migration respectively.  The most intriguing 
finding of this study raises the obvious question, how can two similar proteins elicit 
differential effects on dorsal ruffle formation?  The literature reveals two proteins, 
known to regulate dorsal formation, which can theoretically justify positive or 
negative regulation of dorsal ruffles by RGS RhoGEFs.  Gα12 and Gα13 have been 
shown to regulate dorsal ruffle disassembly [184].  The RGS domain found in LARG 
and P115 increase Gα12/13 GTP hydrolysis inactivating the protein.   One logical 
hypothesis would be that RGS RhoGEF mediated Gα12/13 inactivation would 
increase dorsal ruffle duration/stability.  Our LARG depletion data support this 
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hypothesis.   The P115 data however is contrary to this understanding.  This dorsal 
ruffle response in P115 KD cells can be reconciled if an imbalance exists between 
the Gα12/13 signaling and P115 activation.  For instance Gα12 has been shown to 
preferentially bind LARG compared to Gα13 [207].  If Gα12 is preferentially regulating 
dorsal ruffle turnover in SMCs then one might expect that depletion of LARG would 
have a greater impact the number of dorsal ruffles observed than depletion of P115.  
Further studies will require investigation of differential Gα12 and Gα13 signaling in 
SMC dorsal ruffle formation. 
Conversely Rac1 is a well documented as a positive regulator of dorsal ruffle 
formation [190, 208, 209].  There are a number of studies that suggest increased 
RhoA activity inhibits Rac1 signaling.  Since both LARG and P115 have been shown 
to increase RhoA activity it would make sense that endogenous depletion of the 
GEF would lead to decreased RhoA activity and increase Rac1 mediated dorsal 
ruffle formation.  Indeed it is the case that in P115 knockdown dorsal ruffle formation 
is increased, which would be the expected outcome if RhoA Rac1 antagonism 
regulated dorsal ruffle formation, however this is not the case with LARG 
knockdown.  Again if P115 mediated RhoA activation could somehow bias increase 
Rac1 inactivation we could explain the differential P115 effect.  A spatiotemporal 
explanation for the differential effect of P115 will be investigated with future studies.  
RhoA biosensor studies, pioneered by Klaus Hahn, allow for exquisite visualization 
of real time RhoA activity in migrating cells. Work from the Danuser lab asserts that 
in lamellipodia RhoA activation occurs in a band 2µm from the edge and that cdc42 
and Rac1 act 1.8µm from the edge.  Furthermore temporally RhoA activation occurs 
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initially and after a 40 second delay (relative to protrusion) Rac1 and cdc42 reach 
their peak activation [62]. It is conceivable that discrete differences in localization of 
LARG and P115 to established actin regulating microdomains within dorsal ruffles 
could account for substantial differences in RhoA activation, Rac1 antagonism, and 
dorsal ruffle dynamics.  For instance if the localization of P115 differs from the 
localization of LARG in dorsal ruffles by a fraction of a micrometer it is conceivable 
that RhoA mediated Rac1 inactivation could be biased by the individual GEF 
binding. 
Obviously, investigation to conclusively locate or discount the presence of 
RhoA in dorsal ruffles will be of critical importance to future studies.  Pertz et al. 
based on biosensor experiments, claim that RhoA is not present in dorsal ruffles 
[61].  One caveat of this study is that these observations are based on over 
expressed RhoA in these cells.  RhoA over expression has been shown to 
complicate physiological relevance [210].  Additionally these studies were conducted 
in MEFs not smooth muscle cells.  Since these GEFs are selectively expressed in 
SMC this can only increase the possibility that SMC dorsal ruffles are unique in their 
composition and may contain RhoA while other cell types do not.  One future 
experiment to determine if RhoA is contributory toward dorsal ruffle formation in 
SMCs would be to treat with the RhoA inhibiting compound Y-27632 prior to PDGF-
bb treatment.  If RhoA signaling is indeed decreasing Rac1 activity and dorsal ruffle 
formation we would expect to see increased numbers of dorsal ruffles with Y-27632 
treatment.  
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 It is also possible that signaling proteins that interact exclusively with LARG or 
P115 could cause differential regulation of CDRs.  Four separate publications show 
that LARG and the RhoA effector and actin polymerization protein mDia interact. 
Further bolstering the role for a small GTPase mediated employment of mDia to 
drive actin polymerization in cytoskeletal structures is the link between cdc42 and 
mDia2 in filopodia formation [211].  It is possible that selective activation of actin 
polymerization by LARG mediated recruitment of mDia1 and 2 could stabilize or 
increase the rate of dorsal ruffle formation, and that selective recruitment of mDia by 
LARG and not P115 could explain why a decrease in dorsal ruffle formation is 
observed upon endogenous depletion of LARG and not P115.   
 Our demonstration that the RGS RhoGEFs, LARG and P115, are present in 
dorsal ruffles, provide mechanistic insight into the establishment of polarity and the 
regulation of cell migration in SMC.  Clearly, additional studies will be necessary to 
identify the mechanism that allow for differential regulation of dorsal ruffle formation 
by two highly similar GEFs.  Disparate signaling protein interactions and discrete 
microdomain localization of LARG and P115 are both mechanisms capable of 
eliciting the observed response and will be the focus of further investigation.
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It is known that LARG, PRG, and P115 are activated by association with 
Gα12/13 subunits through their respective RGS domains. However, the precise 
mechanisms that regulate LARG or other RGS RhoGEFs in any cell type (including 
SMC) are poorly understood.  All RGS RhoGEFs contains a Dbl homology (DH) 
domain and a neighboring Pleckstrin homology (PH) domain.  The DH domain is 
found in nearly all RhoGEFs and is thought to enhance the GTP exchange reaction 
through allosteric mechanisms [67].  Although less understood, the PH domain is 
thought to serve a modulatory function and has been shown to bind to membrane 
lipids, the β/γ subunits of heterotrimeric G-proteins, and phosphorylated Ser/Thr 
residues.  Additionally, LARG and PRG but not P115 have a PSD-95/Dlg/ZO-1 
(PDZ) domain that is thought to mediate its interaction with additional proteins 
including the IGF1 receptor and plexins [212-214] as well as a C-terminal region that 
allows for both homo and hetero-oligomerization [72]. LARG has been shown to be 
phosphorylated by the tyrosine kinases, Focal Adhesion Kinase (FAK), and TEC, 
and these phosphorylation events have been associated with LARG activation [215].  
While the precise site has not been mapped, evidence suggests that FAK may 
phosphorylate the LARG DH domain.  
Introduction 
Our interest, based on the expression and effects of PRG in SMC, are 
focused on P115 and LARG signaling in SMC.  A series of experiments by Suzuki et 
al. showed that LARG was indeed phosphorylated and that a mutant lacking the N-
terminus was incapable of being phosphorylated [83]. Despite convincing evidence 
of phosphorylation these studies were conducted in COS cells and TEC was the 
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kinase shown to phosphorylate LARG not FAK.  TEC has not been observed in 
smooth muscle however, limiting the importance of TEC mediated LARG 
phosphorylation studies in our SMC based tissue culture systems.  
 Previous studies in our lab demonstrated that FAK signaling regulates SMC 
phenotype [216, 217].  Based on the available evidence of LARG phosphorylation 
the goal of these studies was to test whether FAK-dependent tyrosine 
phosphorylation of LARG is an important mechanism that regulates RhoA activity in 
SMC.  Our lab has a number of FAK related reagents useful in testing this 
hypothesis including dominant negative and constitutively active forms of FAK.  The 
most powerful tool used to dissect endogenous function of FAK is a FAK deficient 
primary mouse SMC culture.  These cultures are isolated from floxed FAK mice 
using standard techniques, and FAK is then deleted in culture by adenoviral-
mediated expression of Cre recombinase (see Figure 4.1). This method avoids 
selective pressures that are common in cells isolated from conventional knock-out 
mice. 
Transient Transfections and Reporter Gene Assays- 10T1/2 were obtained from 
ATCC. Floxed FAK primary aortic smooth muscle cells  (FFSMC) were isolated as 
previously described [218]. For transfections, cells were cultured in 24 or 48 well 
plates, maintained in 10% serum, and infected with Cre or control virus for 24-48 
hours.  After infection cells were transfected 24 h after plating at 50-60% confluence 
using the transfection reagent, TransIT-LT1 (Mirus, Madison, WI), as per protocol.  
Materials and Methods 
85 
 
The SM22, SM α-actin, and c-fos promoter luciferase reporter constructs have been 
previously described [120]. FAK, SuperFAK, and FRNK constructs were have been 
previously described [217]. 
Immunoprecipitation- Cultured FFSMC lysates were purified and pre-cleared with 
PAS beads.  1.2mg of  lysates were then incubated with 10ul of anti-LARG for 2 
hours.  PAS beads were added to mix for 2 hours prior to washes and westerns 
were performed.  
Western Blots-  Cells were lysed in radio immunoprecipitation assay (RIPA) buffer 
plus protease and phosphatase inhibitors. Protein concentrations were determined 
using the BCA assay (Pierce). Protein lysates were run on an 7 or 10% SDS 
polyacrylamide gel, transferred to nitrocellulose, and probed with indicated 
antibodies Anti-LARG (A kind gift of K. Burridge, UNC-CH) or P-Tyr (Millipore 05-
321).  To achieve separation of 240-260kd proteins 7% mini gels were run until 
150kd proteins were at the bottom of the gel. 
Results 
To  begin to test our hypothesis that FAK was important in regulating LARG 
mediated RhoA activation and SMC specific differentiation we over expressed FAK,  
FAK over expression had no effect on SMC transcription 
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Figure 4.1. Generation of FAK-null Cells.  Multiple aortas are extracted from mice 
that contain the floxed FAK transgene.  Adventitial layers are removed and aortas 
and are digested in elastase and collagenase.  After plating cells are infected with 
Cre adenovirus or control (LacZ) virus to ablate expression of endogenous FAK. 
Western blots contributed by Liisa Smith Ph.D.   
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SuperFAK (a construct with increased activation potential), and FRNK (dominant 
negative) concomitantly with LARG in our tissue culture system.  The effects 
generated by co-transfecting LARG and FAK were unremarkable and revealed little 
effect on SMC specific transcription.  (see Figure 4.2)   
 After seeing no effect with FAK over expression we hypothesized that the 
endogenous levels of FAK were at or above a threshold for maximal FAK mediated 
activation and that FRNK over expression was not adequate at inhibiting FAK 
mediated activation of LARG.  To determine if endogenous FAK was required for 
RGS RhoGEF mediated transcriptional activation we cultured primary aortic SMC 
isolated from mice that possess a floxed FAK transgene.  After Cre mediated FAK 
depletion we co-transfected RGS RhoGEF constructs and smooth muscle specific 
promoters fused to luciferase reporters.  Both wild type and FAK depleted SMCs  
Depletion of FAK has no effect on RGS RhoGEF mediated SMC transcription  
showed similar increases in smooth muscle specific transcription in response to 
RGS RhoGEF depletion. (see Figure 4.3) 
To determine if LARG was significantly phosphorylated on tyrosine residues 
in SMC we conducted immunoprecipitation experiments with LARG and 
phosphotyrosine antibodies.  Figure 4.4 shows that a substantial amount of LARG 
was immunoprecipitated from SMC lysates as evidenced by the amount of LARG 
compared to the input lane.   A phosphotyrosine band was undetectable in that IP 
lane.  We tried the reverse IP using phosphotyrosine  antibodies which again  
FAK does not phosphorylate LARG in SMC 
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Figure 4.2. FAK over expression has no effect on SMC specific transcription.  
FAK, potentiated FAK (SuperFAK), and dominant negative FAK (FRNK) were co-
transfected with a luciferase fused SM22 promoter into 10T1/2 SMC precursors.  
Luciferase activity was measured and expressed as fold increase over empty vector 
and promoter (N=3). 
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Figure 4.3. Effects of endogenous FAK depletion on RGS RhoGEF mediated 
SMC transcription.  Floxed FAK SMCs were infected with control or Cre virus to 
deplete FAK expression.  Cells were then co-transfected with the indicated RhoGEF 
and luciferase fused SMC promoters SM22 or SM α-actin. Luciferase activity was 
measured and expressed as fold increase over control virus transfected with empty 
vector and promoter (N=3).  
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Figure 4.4.  LARG is not tyrosine phosphorylated in SMC.  1.2mg of SMC lysate 
were pre-cleared with PAS beads and incubated with anti-LARG antibody for 1 hour 
prior to IP.  No P-Tyr signal was detected in LARG IP lane. 
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showed that there was no phosphorylated LARG in SMC lysates.  When a western 
blot is performed on SMC lysates with a phosphotyrosine antibody there is a 
substantial phosphor-tyrosine band that emerges at around 250 KD.  Under close 
investigation these bands reveal that there are actually two substantial phosphor-
tyrosine bands at approximately 260 and 240 KD and that there is no phosphor-
tyrosine band that correlates with LARG in SMC lysates (Figure 4.5).  
 
Our original hypothesis was that FAK-dependent tyrosine phosphorylation of 
LARG was an important mechanism that regulates RhoA activity in SMC.  However, 
we did not observe detectible levels of LARG tyrosine phosphorylation in our 
studies, a result in disagreement with previous reports.  Iwanicki et al show, in 
fibroblasts, that PRG is tyrosine phosphorylated by FAK in response to LPA 
treatment[219].  Chikimi et al. claim that both LARG and PRG are phosphorylated by 
FAK but focus mainly on PRG and only show one instance of LARG phosphorylation 
in an IP with an input of ~50mg.  Additionally their studies were conducted in HEK 
293 cells not SMC. Suzuki et al. do show that TEC can phosphorylate LARG but 
these studies were done in COS lysates and TEC is not expressed in smooth 
muscle [83].  Our negative data can be reconciled by two possibilities.  The first is 
that tyrosine phosphorylation of LARG does occur in cell types other than SMC.  The 
second possibility is that other groups who have observed tyrosine phosphorylation 
of LARG were mistaken. 
Discussion 
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Figure 4.5. FAK depletion has no effect on observed P-tyr bands near 250 KD. 
FFSMC were treated with control or Cre virus to deplete endogenous FAK 
expression.  8% SDS Page gels were extensively run to reveal that the observed P-
tyr bands ~ 260 KD and 240 KD bracket LARG at 245 KD.   
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LARG and PRG are immense proteins of 1544 and 1522 AA respectively.  
Logistically running and separating these ~250 kiloDalton proteins can be difficult.  
Further confounding the ability to study these two GEFs on an individual basis, 
LARG and PRG have been shown to heterodimerize [72].  Because of their similarity 
in size and heterodimerization it is possible that if large amounts of LARG were 
immunoprecipitated then residual tyrosine phosphorylated PRG could have co-
immunoprecipitated and contaminated the samples. It should be noted that in 
laterfractionation experiments using super resolved gels we observed that the P-tyr 
band at 240 KD correlates with the nuclear specific PRG (data not shown).  
Given the similarity with LARG there is a likelihood that PRG can function 
redundantly or in lieu of LARG.  Indeed in previous RhoA activity assays there was a 
small but consistent contribution of PRG in S1P mediated RhoA activation.  One 
intriguing prospect is that tyrosine phosphorylation, possibly mediated by FAK, could 
preferentially activate or inhibit PRG over LARG.  Given size and domain structure 
one would expect these proteins to function and localize identically but this is not the 
case.  In fact in fractionation experiments LARG and PRG have both been shown in 
the nuclear and cytoplasmic fractions but a robust P-tyr band was seen in the 
nuclear fraction that corresponded exactly with one of the PRG doublet bands and 
not LARG.  While it would be premature to draw the conclusion that the PRG band 
seen in the nuclear fraction is a preferentially tyrosine phosphorylated version of the 
protein it is an interesting theory and could illuminate a mechanism to target two 
otherwise very similar proteins to different compartments of the cell.  Regardless 
PRG expression levels are fairly low in SMC and over expression generated 
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underwhelming effects on SMC transcription.  Because of this PRG has been of 
limited interest in these studies and the project was abandoned.   
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An increasing number of studies outline the importance of LARG signaling in 
a number of physiological conditions including growth, migration, and differentiation 
[75, 76, 83, 87, 89, 124, 157].  While the importance of LARG signaling has been 
underscored we have a poor understanding of how LARG localization regulates its 
activity.  The evolutionary processes that have driven the divergence from one 
common RGS RhoGEF like the DRhoGEF in drosophila or rhgf1 in C. elegans to the 
three RGS RhoGEFs found in higher order vertebrates had a reason to do so.  The 
significance of RGS RhoGEF divergence and the signaling specific to LARG is not a 
topic that has been thoroughly studied, and understanding the domains that regulate 
LARG function is imperative in understanding protein function as a whole.  LARG 
contains two N-terminal NLSs, PDZ, RGS, and DHPH domains as well as an 
extreme C-terminal coil coil region.  Some PDZs have been shown to bind C-
terminal polypeptides; others appear to bind internal (non-C-terminal) polypeptides. 
The RGS domain is found in GTPase-activating proteins for heterotrimeric G-protein 
α-subunits that promote GTP hydrolysis by the α subunit of heterotrimeric G-
proteins, thereby inactivating the G protein and rapidly switching off G protein-
coupled receptor signaling pathways.  The DH domain contains about 200 residues 
shown to encode GEF activity specific for a number of Rho family members and the 
PH domain contains about 100 residues that may have multiple functions or different 
functions in different proteins, including signal transduction, membrane anchoring, 
and protein-protein interaction [220].  This combination of domains results in a 
protein with a number of signaling properties.  Complete understanding of LARG 
Introduction 
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signaling will require studying subtle changes in domain structure and composition, 
post translational modifications, and subcellular localization.  
  Grabocka et al. have shown that there is a functional and unique NLS in the 
N-terminus of LARG and that oligomerization, regulated by a C-terminal coil coil 
region, prevents nuclear localization of LARG. They went on to show that leptomycin 
treatment results in accumulation of LARG in the nucleus suggesting that LARG 
cycles between the cytoplasm and nucleus in a CRM-1 dependent manner [64].  The 
authors, however, stop short of mapping the NES and conduct their studies primarily 
in COS cells.  Additionally these authors stop short of posing a mechanism for the 
observed variations in localization.  Specific functions for P115 RhoGEF are evident 
by the differences in domain structure and expression pattern, lymphocyte and 
neuronal and apoptotic specific effects for instance [221-224].  The differences 
between LARG and PRG function are much less well known.   
Nuclear localization has previously been considered an important property for 
transcription factors, chromatin modification proteins like HDACs and HATs, and 
other DNA binding/modifying proteins.  There is mounting evidence however that the 
nucleus can function as a microdomain for specific cellular events not restricted to 
transcriptional regulation.  There is evidence to suggest that RhoA is present and 
may be active in the nucleus. Balboa et al. showed in cell fractionations that RhoA is 
present in the nuclear fraction [225].  More recently Li et al. showed in several cell 
types that RhoA is localized in the nucleus with high concentrations in the nucleolus 
and that the concentration of nuclear RhoA increases when cells undergo 
tumorgenesis [226].   Most importantly other GEFs known to activate RhoA including 
98 
 
ECT2 and NET1 have been detected in the nucleus [63, 227]. Work from our own 
lab has shown that the actin polymerizing RhoA effector Dia is also present in the 
nucleus.  Together these data represent an intriguing picture by placing together the 
necessary components to orchestrate RhoA mediated actin dynamics in the nucleus.  
We have shown that LARG localization is tightly regulated by an N-terminal NLS and 
a C-terminus that regulates nuclear localization by an unknown mechanism.   This 
goal of this study was to determine how nuclear localization of LARG is regulated 
and determine how this localization governs its ability to regulate smooth muscle 
specific gene transcription.  Based on the emerging evidence of nuclear 
microdomain signaling we hypothesize that high nuclear concentrations of LARG will 
increase SMC specific transcription in a RhoA dependent manner.   
Plasmids and Reagents- Full Length LARG and PRG were generous gifts of T. 
Kozasa (University of Tokyo, Tokyo, Japan)  LARG and PRG were then subcloned 
into pcDNA 3.1 and eGFP expression vectors. Antibodies to LARG and PRG were 
kind gifts of K. Burridge (UNC Chapel Hill).  FL LARG spans AA 1-1544, ΔNLS 
LARG AA 41-1544, ΔN LARG AA 360-1544, ΔC LARG AA 1-1161, ΔNLSΔC LARG 
AA 41-1161, ΔNΔC LARG AA 1079-1161.  All LARG constructs were engineered 
with 5’ KPN and 3’ APA sites and shuttled between pcDNA 3.1 and eGFP 
expression vectors. 
Materials and Methods 
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Cell Culture, Transfections, and Reporter Assays- The 10T1/2 and SMC cell 
cultures, transient transfections, and promoter luciferase assays have been 
previously described [44, 120].   
Localization by Immunofluorescence- 10T1/2 cells were transfected with GFP 
tagged versions of indicated LARG truncations.  At least 100 cells were scored from 
three separate experiments under three criteria nuclear, cytoplasmic, or diffuse 
defined as mostly nuclear, a defined nuclear shadow, and an overall even 
distribution, respectively. 
Results 
As discussed in chapter 2 of this dissertation, LARG was shown to play a 
dominant role in S1P mediated SMC specific transcription.  For these reasons 
emphasis was placed on LARG above PRG and P115 in the study of subcellular 
localization and possible mechanisms for spatial restriction of LARG protein.  LARG 
consists of several different domains and is modular in structure.  Analysis for 
conserved domains suggests that, from N to C terminus there are two nuclear 
localization sequences, a PDZ domain, and RGS domain, a DH/PH or GEF domain 
a coil coil domain on the extreme C terminus.  Five truncations were made and 
subcloned into expression vectors using standard subcloning techniques (see Figure 
5.1).  These truncations were subcloned into a GFP expression vector and over-
expressed in  
LARG localization is tightly regulated between nuclear and cytoplasmic fractions in 
SMC 
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Figure 5.1. Sub-cellular localization of LARG is regulated by N and C-terminal 
domains. A.  Schematic representing six LARG variants made to study localization 
and transcriptional activation.  B.  Quantification of LARG variant localization scored 
for nuclear, cytoplasmic, or diffuse patterns.   
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10T1/2 SMC precursors.  At least 100 cells were counted and scored under three 
categories, cytoplasmic, diffuse, and nuclear, with diffuse defined as an equal 
distribution amongst the entirety of the cell and either cytoplasmic or nuclear defined 
as an observable gradient existing between the compartments.  Full length LARG 
was mostly cytoplasmic or diffuse with only a small fraction nuclear, around 2%.  
Truncation of the most extreme N-terminal NLS achieves the expected result 
inducing increased cytoplasmic localization. Additional truncation of the N-terminus 
slightly increases the cytoplasmic localization.  This result is not surprising based on 
a predicted weak NLS in this region.  Additionally the ΔN truncation removes the 
PDZ domain.  This suggests that, upon over expression, the PDZ domain itself does 
little to regulate nuclear localization.  The most robust change in localization occurs 
when the extreme C terminus of the LARG protein is cleaved which results in a shift 
from 2% nuclear to 73% nuclear with the remainder of cells exhibiting a diffuse 
expression pattern.  Cleaving the C-terminus removes a coil coil region which 
regulates homodimerization and possibly heterodimerization with PRG. 
To determine what effect LARG localization had on SMC specific transcription 
A luciferase based system was used to assess the effect over expression had on 
promoter firing.  Three promoters were tested including SM22 and SM α-actin both 
indicators of smooth muscle specific transcription and C-fos as an indicator of 
growth specific transcription.  Results were normalized against a TK minimal 
response promoter. We did not observe significant changes with a c-fos luciferase 
reporter with co-transfection of a LARG and LARG truncation constructs.  The full 
Over expression of nuclear LARG increases SMC specific transcription 
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length LARG as well as the ΔNLS LARG and the ΔN LARG all had similar effects 
generating a 3-5 fold increase in smooth muscle specific transcription.  As seen with 
SM22 and SM α-Actin the most robust effect was seen with the ΔC LARG construct.  
This mainly nuclear construct increased SM α-actin and SM22 transcription by 
approximately 6 and 8 fold respectively or roughly twice the effect of full length 
LARG (see Figure 5.2). 
We have shown that nuclear targeted LARG is twice as effective at increasing 
SMC specific transcription as the more cytoplasmic full length LARG.  The initial 
observations of this study support the work done in COS cells by Grabocka et al. 
that characterized the localization of LARG [64].  The most interesting and novel 
finding of these studies was that the nuclear targeted version of LARG (ΔC LARG) 
was by far the most effective at increasing RhoA mediated increases in SMC 
differentiation gene expression.   
Discussion 
Additional studies related to nuclear localization of LARG in SMC have 
focused on the endogenous localization states.  Conclusive data answering these 
important questions has remained elusive.  Cellular fractionation and subsequent 
western blotting suggest that there are nearly equal proportions of endogenous 
nuclear and cytoplasmic LARG throughout the cell (data not shown).  This is in 
sharp contrast to over expression studies, by our lab and others, that suggest LARG 
is predominantly found in the cytoplasm unless a C-terminal truncations is induced.   
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Figure 5.2. C-terminal truncation of LARG increases SMC specific 
transcription.  LARG truncations were co-transfected with luciferase fused SMC 
specific promoters into 10T1/2 SMC precursors.  Data is expressed as fold increase 
over empty vector co-transfection (N=3). 
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This discrepancy in observed localization could be attributed to artifacts of 
over expression.  Grabocka et al suggest that the C-terminal is required for nuclear 
export of LARG but are not able to conclusively show the mechanism that regulates 
this export. It is evident that LARG localization is an active process but whether the 
C-terminal deletion causes decreased nuclear export or increased nuclear import 
remains in question.  These questions could be addressed by tracking photo 
activatable pools of LARG and LARG truncations or inversely through FRAP 
experiments.  We also examined whether LARG localization was regulated by 
various agonists.  So far none of the reagents studied have been able to significantly 
increase either cytoplasmic or nuclear endogenous LARG localization in SMC.  
Likewise, to address if cytoplasmic or nuclear pools are differentially activating RhoA 
nucleotide free G17A Rho pulldowns could be performed on fractionated lysates 
previously stimulated with various agonists.   
The robust localization variation in LARG and the multiple domains and motifs 
within the protein that allow for regulation of localization make it an attractive GEF to 
conduct spatially regulated RhoA activation studies.  Using the RhoA biosensor and 
FRET based approach has been attempted but obtaining reliable results has been 
difficult.  The rigors of siRNA transfection in a cell type already crippled by robust 
RhoA over expression limits the reliability of biosensor based data.   
One worthwhile series of experiments to arise from these studies came when 
testing if serum stimulation increased LARG localization on short time scales.  While 
there were no significant changes in nuclear versus cytoplasmic LARG we did 
observe for the first time LARG in circular dorsal ruffles.  The function of LARG in 
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these structures is the subject of intense investigation previously discussed in this 
dissertation. 
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The largest single class of pharmacological targets are G-Protein Coupled 
Receptors (GPCRs) with estimates ranging from 27% to 60%; a class to which the 
S1P receptors belong [228, 229]. According to the CDC National Vital Statistics 
Report of 2006 the leading cause of death in the U.S. is cardiovascular disease.  
The body of this dissertation has explored and explained signaling pathways that 
regulate SMC phenotype.  One of the most important revelations in SMC biology, 
studied in depth in this dissertation, is that S1P regulates SMC differentiation and by 
extension the pathogenesis of many cardiovascular disease states. This has direct 
implications toward the development of pharmaceuticals targeted at regulating 
vascular homeostasis.  
Introduction 
Despite an intense focus on finding new categories and classes of targets for 
pharmacological intervention, relatively incremental progress has been made in the 
last several years.  The utilization of huge screening protocols as opposed to 
methodical investigation of the components and kinetics of signal transduction is one 
factor that has complicated the refinement of drug discovery in recent years.  There 
are many drugs, now in use, whose mode of action or specific pharmacology is 
poorly understood.  This lack of understanding has hampered our ability to predict 
the off target effects of many drugs currently on the market, and has only increased 
the incidence of clinically relevant polypharmacology associated with newly identified 
compounds [228].   Consequently the push to further investigate and develop 
compounds with a high degree of specificity to functional pharmacological targets 
with well defined pathways is ever increasing.  The discoveries surrounding S1PR2 
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mediated regulation of SMC differentiation exemplifies this confluence of 
pharmacological relevance and biological understanding.  
James Black, winner of the 1988 Nobel Prize in Physiology or Medicine, said 
“the most fruitful basis for the discovery of a new drug is to start with an old drug” 
[230]. If this is indeed true than the discovery of S1PR specific drugs should prove 
exceptionally productive.  While still in their infancy S1PR targeted drugs are of 
intense interest and are just beginning to be developed and fully investigated.  Their 
use in traditional Chinese medicines dates back centuries.  Extracts from the fungus 
Isaria sinclairii have revealed a sphingosine mimetic compound named FTY720 or 
fingolimoid (see [231, 232] for review).  While initially tested as an 
immunosuppressant for kidney transplants more recent testing has shown a 
particular efficacy for immunosuppressive treatment of multiple sclerosis.  The 
compound was so effective that in June 2010 the FDA unanimously recommended 
FTY720 be approved as the first oral medication for MS. 
FTY720 has shown a high affinity for S1PR 1, 3, 4, and 5 with relatively little 
affinity for S1PR2.  The specifics of the FTY720 mode of action beyond S1PR 
binding are a matter of some debate in the field. The emerging consensus shows an 
initial wave of high specificity binding and activation [233].  Additional evidence 
suggests that while S1P promotes a reversible internalization, the internalization 
induced by FTY720 binding is irreversible, triggering ubiquitination and proteasome 
mediated degradation, rendering endogenous S1P unresponsive [234, 235].  
Beyond the binding affinities and receptor dynamic specifics the ability for FTY720 to 
inhibit lymphocyte egress from lymphatics is unmistakable.   
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While the role of FTY720 and other S1P analogs has been defined in 
lymphocyte trafficking, the role these compounds play in the regulation of vascular 
homeostasis and disease is not well understood.  Mouse model evidence suggests 
that the S1P receptors are viable targets for modulating vascular patterning.  Keul et 
al. were able to show, in an atherosclerosis prone Apo-E mouse, that FTY720 
treatment can reduce lesion volume by 63% [236].  Also dosage studies suggest that 
stent-delivered high concentrations of FTY720 at the sites of acute vascular injury 
may inhibit restenosis and hyperplasia [237].  Other vaso-protective functions have 
been observed with FTY720 including anti-hypertensive effects and protection from 
ischemia/reperfusion injury [238, 239]. 
S1P levels have proven to be a strong indicator of cardiovascular disease in 
general [118, 240].  But given the high basal level of S1P signaling we hypothesize 
that general negative regulatory methods are a major factor in directing pathway 
specification.  Furthermore varying the expression levels of S1P receptors is a 
means that has already been shown to preferentially increase S1P mediated 
signaling [113].  While extensive in-vitro and mouse model studies have been done 
there is little or no published data concerning S1P receptor expression in human 
atherosclerotic plaques.  The goal of this study was to determine if S1PR2 
expression varies between healthy and diseased arterial vasculature in humans. 
Human Aortic Protein Isolation- Office of Human Research Ethics (OHRE) and 
Institutional Review Board (IRB) approval was obtained to procure aortas, from 
Materials and Method 
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human cadavers, which presented with advanced atherosclerotic plaques.  The fat 
was removed from the aorta and all remaining layers were kept intact.  Rings 
approximately 5mm wide were sliced from the aortas in “healthy” areas with no 
observed plaque formation as well as in areas with advanced lesion formation.  
Transmural wedges were cut, snap frozen, and homogenized in RIPA buffer.  The 
tissue samples were lysed in RIPA and purified by centrifugation and equalized by 
BCA assay as per protocol.  Equal amounts of protein were loaded on an SDS 
PAGE gel and western blots were performed. 
Result 
In a resected section of aorta from a human cadaver we show that 
atherosclerotic vasculature has increased S1PR2 expression and decreased SM α-
Actin expression compared to neighboring non-diseased aorta (see Figure 6.1) SMC 
with no adventia, plaque, fibrous cap, adventia only, and fat only layers were also 
separated and individually probed for S1PR2 and SMC markers.  Plaque tissues 
(which included SMC layer) from the diseased aorta showed the most robust 
expression of S1PR2. 
S1PR2 expression is up regulated in atherosclerotic vasculature 
  
 
 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. S1PR2 and SM α-Actin levels in healthy and atherosclerotic human 
aortas. A) Schematic of disc and wedge resection method for procuring protein from 
tissue samples. B)  S1PR2 and SM α-Actin expression in healthy and diseased 
aorta. 
 
112 
 
Given the abundance of S1P in circulation we have hypothesized that 
negative regulation of receptor expression is a viable means of directing S1P 
specific signaling.  Despite the interest in S1P mediated regulation of CVD 
progression, very little is known concerning receptor expression variation in human 
models of disease.  Previously our lab and others have shown that the S1PR2 
specifically drives the S1P mediated differentiation of SMCs and that this 
differentiation is important in development as well as disease.  Given these finding 
we were curious what changes might occur in S1PR2 expression in an advanced 
atherosclerotic lesion.  The data we have generated to address this question reveals 
a very large delta with respect to S1PR2 in healthy and diseased aortic tissue.  This 
degree of expression variation begs a host of questions and additional experiments.  
Discussion 
One caveat of the human aorta western blot experiment relates to the 
composition of a plaque.  An atherosclerotic plaque, by nature, is a very complex 
lesion consisting of a number of cell types. It is possible that the variation in 
expression is due to cell type specific expression of S1PR2.  During dissection of the 
aortas, an attempt was made on separate areas of healthy and diseased aortas, to 
separate the individual layers and assess protein expression in a layer specific 
manner.  It did appear that protein purified from just the medial SMC and intimal EC 
lacking the fat and adventitial layers of healthy and atherosclerotic tissue mirrored 
the gross protein purifications.  Additionally purified protein isolated from just the 
fibrous cap of the lesion showed very little expression of S1PR2 (data not shown).  If 
the changes in S1PR2 are attributable to cells other than those of smooth muscle 
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origin they would need to be those that compose the inner layers of the plaque 
excluding the tissue that composes the fibrous cap.  The most direct way to answer 
these questions would be to conduct IHC analysis of S1PR2 expression in situ, with 
other markers that would allow identification of SMCs, lymphocytes, fibroblasts, 
macrophages, and other cell types.  Additionally these data bring into question what, 
if any, changes are made in S1P receptor expression in other vascular disease 
states including hypertension and restenosis, and if these expression changes occur 
preferentially in SMC of specific origins.   
 Based on previous studies surrounding S1P receptor expression and 
signaling in cell culture and animal models we have a few interesting hypothesis 
about how S1P treatments could be employed to combat CVD.  Given the already 
high molar concentration of S1P in serum, combined with the very dynamic changes 
in receptor expression, systemic delivery of S1P would not be the preferable method 
of delivery.  Given the unknowns surrounding receptor expression and origin-specific 
smooth muscle signaling the possibility off target effects resulting from systemic 
delivery would be too great. In short there are just too many variables to contend 
with.  Systemic prophylaxis with a S1PR2 specific agonist aimed at inhibiting 
migration and proliferation of SMC may show some merit.  Based on results from our 
lab and others, increasing S1PR2 specific activation in SMC should serve to 
stabilize SMC populations by increasing the differentiated state and inhibiting 
proliferation and migration.  While this would not be preferable during development 
as the aforementioned processes are critical in proper vascular patterning, 
114 
 
administration of an S1PR2 specific agonist after the initial formation of a fatty streak 
could conceivably inhibit progression to clinical atherosclerosis.   
  In instances such as balloon injury, coronary artery bypass grafts (CABG), 
and other acute arterial injury, localized delivery of an S1PR specific drug by a drug 
eluting stent is also worthy of clinical consideration.  If a coating could be engineered 
to elute agonist specific to S1PR1 and 3 for a short window preceding elution of an 
S1PR2 specific agonist SMCs could be directed to first populate and proliferate at 
the area of injury then pushed toward a differentiated state to quickly and efficiently 
construct matured robust arterial vasculature capable of handling elevated arterial 
pressure.  Another area ripe for the inclusion of S1P assisted vascular maturation is 
in the biopolymer based tissue scaffolding arena.  A number of pathologies require 
arterial replacement including instances of CABGs and patients with kidney failure 
who require peripheral grafts for dialysis access.  There are many instances when 
patients need engineered tissues because of a lack of conduit.  S1PR specific 
direction of xenograft development prior to implantation could be very effective in the 
production of synthetic grafts.  Taken together the efficacy of S1P analogs as 
pharmacologic agents is unmistakable and the potential for attenuation of CVD 
progression at the level of S1P receptors is high.  These facts beg further 
investigation of S1P signaling as a means to treat CVD. 
The entirety of this dissertation was borne out of the question, how does S1P 
regulate SMC phenotype?  Attempts to answer that question revealed three relevant 
Dissertation Overview and Conclusions 
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areas of study explored in this dissertation.  The second, fourth, and fifth chapter of 
this dissertation are intensely focused, and definitively explain, how S1P regulates 
smooth muscle differentiation.  The third chapter of this dissertation explores the 
importance of the S1PR2 downstream effectors, LARG and P115, in regulating the 
transition of SMC from a static to motile state and eventual de-differentiation.  The 
last chapter of this dissertation examines the clinical relevance of these findings.   
 Prior to beginning this thesis work little was known about the upstream 
regulators of RhoA in the context of smooth muscle specific transcription.  An 
intense focus on the signaling events downstream of RhoA activation of SMC 
revealed the RhoA-MRTF axis as the regulatory mechanism for SMC specific 
differentiation.  These findings, along with the realization that S1P activated RhoA in 
a variety of cell types, revealed a gap in our understanding of the signaling that 
regulates SMC differentiation.  Chapters 2, 4, and 5 of this dissertation fill this gap in 
the SMC field.  Chapter Two is a reiteration of a paper published in ATVB and is 
titled S1PR2 Signals Through LARG to Promote SMC Differentiation.  This paper 
parses the signaling that occurs after S1P binding to surface receptors at the plasma 
membrane until SMC differentiation specific genes are transcribed.  In brief the 
results conclusively show that SMC differentiation is regulated by S1P through 
S1PR2 and that Gα12/13 and the RGS RhoGEFs, upon overexpression, can stimulate 
SMC-specific transcription.  Finally we go on to show that LARG alone is necessary 
in generating significant S1P mediated increases in RhoA activity as well as SMC 
specific transcription, message, and protein expression.   
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 Navigating the intricacies of a thesis project is not, nor should it be, a strictly 
linear progression.  During the course of the studies important questions were asked 
and answered that didn’t necessarily fit into a larger publication.  Chapters 4 and 5 
represent these types of findings.  Other cell types have shown a role for FAK in 
regulating LARG activity.  We chose to test if FAK phosphorylated LARG in SMC.  
We show that FAK over expression or depletion had no significant effects on LARG 
mediated SMC transcription and that, in our hands, FAK does no phosphorylate 
LARG in SMC.  This negative data did not fit well into our planned publications nor 
was it worth the effort needed to develop into a standalone publication.  Despite 
these caveats the inability of FAK to phosphorylate LARG in SMC is an important 
observation and is worthy of inclusion with this dissertation.  Chapter 5 focused on 
the subcellular localization of LARG and the effects this had on the proteins ability to 
activate RhoA.  We show that LARG localization is tightly regulated between nuclear 
and cytoplasmic fractions and that the subcellular localization of LARG has 
substantial effects on SMC specific transcription.  While these findings alone are 
short of publication readiness, this is interesting data worthy of further investigation.  
The emerging paradigm of subcellular localization, nuclear localization in particular, 
of small GTPases as a regulatory mechanism would make LARG an attractive GEF 
to study in this respect.  Time considerations and other studies forced us to shelve 
this project, thought the questions surrounding this project would likely yield 
interesting and possibly compelling results. 
 Chapter 3 of this dissertation approaches the regulation of SMC phenotype 
with a focus on the processes that regulate the de-differentiation of SMC.  The 
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clinical relevance of these studies are more tangible since the synthetic migratory 
state is critical in the pathogenesis of atherosclerosis as well as neointimal 
hyperplasia.  We hypothesize that dorsal ruffling is an important process in 
establishing polarity and initiating migration in the reversion of differentiated to 
migratory SMC.  We show that LARG and P115 are localized to dorsal ruffles and 
that the depletion of these GEFs differentially effects dorsal ruffle formation as well 
as SMC migration.  These data are a strong foundation for future studies that will 
focus on the importance of RhoA, LARG, and P115 in the regulation of dorsal ruffles 
and migration.  Further studies will be conducted to determine how LARG and P115 
differentially regulate dorsal ruffles and migration as well as to conclusively 
determine the presence or absence of RhoA in SMC. The combined conclusions of 
Chapters 1-5 are summarized in figure 6.2  
 Chapter 6 focuses on the translational perspectives of S1P signaling in 
arterial vasculature.  The realization that GPCRs, like the S1P receptors, are the 
most common target of manufactured pharmaceuticals, and that S1P could play an 
important role in vascular regulation requires an investigation of the possible 
therapeutic use of S1P related agonists in the treatment of CVD.  To first show the 
possibility of efficacy this chapter discusses the recent refinement of isaria sinclairii 
resulting in purification of the compound FTY-720, recently approved for the 
treatment of multiple sclerosis.  S1P as a predictor of coronary artery disease is 
referenced as well as the protective role S1PR2 plays in the inhibition of neointimal 
hyperplasia after acute vascular injury.  We show that in human atherosclerotic 
lesions there is a robust increase in S1PR2 expression.  Based on this observation 
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and the observations made concerning the role S1PR2 and its downstream effectors 
play in regulating SMC differentiation and phenotypic reversion to a migratory state 
we hypothesize that S1P receptor agonists could be used in clinically relevant ways 
to inhibit the progression of atherosclerotic plaque, ameliorate pathological 
neointimal hyperplasia, and in the general regulation of vascular homeostasis.   
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Figure 6.2  SMC signaling conclusions.  Of the 5 known S1P receptors S1PR2 
increases RhoA activity.  Through Gα12/13 S1PR2 can activate RhoA through LARG, 
PRG, and P115.  LARG is the most efficient RGS RhoGEF at increasing RhoA 
activity in response to S1P and is required for S1P mediated increases in SMC 
transcription.  LARG and P115 have differential effects on dorsal ruffle formation 
resulting in the LARG mediated inhibition and P115 mediated increase in SMC 
migration. 
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